1 2	Development and Validation of a Paralimbic Related Subcortical Brain Dysmaturation MRI Score in Infants with Congenital Heart Disease
3 4	William T. Reynolds, BS ^{*1} , Jodie K. Votava-Smith, MD ^{*2} , George Gabriel, PhD ^{*4} , Vince Lee, BS ⁵ , Vidya Rajagopalan, PhD ² , Yijen Wu, PhD ⁴ .
5	XiaoQin Liu ⁴ , MD, Hisato Yagi, PhD ⁴ , Ruby Slabicki, BA ⁵ , Brian Gibbs, PhD, ⁴
6	Nhu N. Tran, PhD ³ , Molly Weisert, MD ² , Laura Cabral PhD ⁵ ,
7	Subramanian Subramanian, M.D ⁵ , Julia Wallace, BA ⁵ , Sylvia del Castillo, MD ⁶ ,
8	Tracy Baust, BA ⁷ , Jacqueline Weinberg, MD ⁸ , Lauren Lorenzi Quigley, PhD ¹⁰ , Jenna Gaesser
9	MD ⁹ , Sharon H. O'Neil PhD ¹¹ , Vanessa Schmithorst PhD ⁵ , Rafael Ceschin, PhD** ⁵
10	Cecilia Lo, PhD ^{**⁴} , and Ashok Panigrahy, MD ^{**⁵}
11	
12 12	1 Department of Riemodical Informatics, University of Dittsburgh School of Medicing, Dittsburgh, DA
13 14	2. Department of Pediatrics Division of Cardiology Children's Hospital Los Angeles and Keck School of
15	Medicine, University of Southern California, Los Angeles, CA
16	3. Fetal and Neonatal Institute, Division of Neonatology Children's Hospital Los Angeles, Department of
17	Pediatrics, Keck School of Medicine, University of Southern California, Los Angeles, CA
10 19	5 Department of Pediatric Radiology, Children's Hospital of Pittsburgh of UPMC and University of Pittsburgh
20	School of Medicine, Pittsburgh, PA
21	6. Department of Anesthesiology, Critical Care Medicine Children's Hospital Los Angeles, Los Angeles, CA
22	7. Department of Critical Care Medicine, University of Pittsburgh, Pittsburgh, PA
23 24 25	 Department of Cardiology, University of Pittsburgh School of Medicine, Pittsburgh, PA Department of Neurology and Child Development, University of Pittsburgh School of Medicine, Pittsburgh, PA
26	10. Cardiac Neurodevelopmental Care Program, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA
27 28 29	11. Division of Neurology and The Saban Research Institute, Children's Hospital Los Angeles, Department of Pediatrics, Keck School of Medicine, University of Southern California, Los Angeles, CA
30	*co-first authors; **co-senior authors
31	
32	
33	Short Title: Subcortical paralimbic abnormalities and outcomes in infant and CHD mouse model
34	
35	
36	Address Correspondence and Reprint Request to:
37	Ashok Panigrahy, MD
38	Department of Pediatric Radiology Children's Hagnital of Dittahurgh of LIDMC
39 40	4401 Penn Avenue
41	Pittsburgh, PA 15224
42	Tel: 412-692-5510
43	Fax: 412-864-8622
44 45	apanigrahyranjan@gmail.com

46 Abstract

47 Background

48 Brain magnetic resonance imaging (MRI) of infants with congenital heart disease (CHD) shows brain immaturity

49 assessed via a cortical-based semi-quantitative score. Our primary aim was to develop an infant paralimbic-related

50 subcortical-based semi-quantitative dysmaturation score, a brain dysplasia score (BDS), to detect abnormalities in

- 51 CHD infants and predict clinical outcomes. Our secondary aim was to validate our BDS in a preclinical mouse
- 52 model of hypoplastic left heart syndrome.

53 Methods

54 A paralimbic-related subcortical BDS, derived from structural MRIs of infants with CHD, was correlated with

55 clinical risk factors, regional cerebral volumes, feeding and 18-month neurodevelopmental outcomes. The BDS

56 was validated in a known CHD mouse model named *Ohia* with two disease-causing genes, *Sap130* and *Pchda9*. To

57 relate clinical findings, RNA-Seq was completed on *Ohia* animals.

58 Findings

- 59 BDS showed high incidence of paralimbic-related subcortical abnormalities (including olfactory, cerebellar, and
- 60 hippocampal abnormalities) in CHD infants (n=215) compared to healthy controls (n=92). BDS correlated with
- 61 reduced cortical maturation, developmental delay, poor language and feeding outcomes, and increased length of
- 62 stay. *Ohia* animals (n=63) showed similar BDS findings, and RNA-Seq analysis showed altered
- 63 neurodevelopmental and feeding pathways. *Sap130* mutants correlated with a more severe BDS whereas *Pcdha9*
- 64 correlated with a milder phenotype.

65 Interpretation

- 66 Our BDS is sensitive to dysmaturational differences between CHD and healthy controls, and predictive of poor
- 67 outcomes. A similar spectrum of paralimbic-related subcortical abnormalities exists between human and Ohia
- 68 mutants suggesting a common genetic mechanistic etiology.

69 Funding

- 70 National Library of Medicine, Department of Defense, National Heart, Lung, and Blood Institute, National Institute
- 71 on Aging, Southern California Clinical and Translational Sciences Institute, Additional Ventures Foundation,
- Saban Research Institute, Children's Hospital Los Angeles Clinical Services Research Grant, and National Institute
- 73 of Nursing Research. Funding award numbers can be found in the acknowledgment section.

74 Non-standard Abbreviations and Acronyms

- 75 ECM: Episcopic Confocal Microscopy, CHD: congenital heart disease, HLHS: hypoplastic left heart syndrome,
- 76 MRI: magnetic resonance imaging, , WMI: white matter injury, GA: gestational age, PCA: post-conceptional age,
- 77 BDS: brain dysplasia score.

78 Keywords

- 79 Olfactory Bulb, Hippocampus, Cerebellum, Feeding Outcome, Neurodevelopmental Outcome, Ohia HLHS Mouse
- 80 Mutants
- 81

82 Research In Context

83 Evidence before

84 The number of clinical and research MRI studies in neonatal/infant CHD subjects has increased dramatically in the

85 last two decades. Previous studies have developed brain MRI scores that have focused on cortical structural

86 maturation and acquired brain injury. Paralimbic-related subcortical regions are important for the development of

- 87 cognitive and visuomotor functions in early development. Levering a large infant brain MRI dataset and a large-
- scale genetic mouse screen, we theorized that a paralimbic-related subcortical brain MRI score could assist
- 89 clinicians with outcome prediction in CHD infants.

90 Added Value

91 This work aims to develop a subcortical morphological scoring system that could be applied to either clinical or

92 research MRI scans and could improve the ability of clinicians and neuroradiologists to predict not only those at

93 risk for suboptimal neurodevelopmental outcomes but also associated co-morbidities. We discovered not only are

94 there paralimbic-related subcortical structural abnormalities that a brain MRI score can detect but also that this

score predicted poor language outcomes, poor feeding outcomes, and increased post-surgical length of stay. We

also found that the genetic model of hypoplastic left heart syndrome, the most severe form of CHD, also

97 demonstrated a similar pattern of paralimbic related subcortical brain abnormalities.

98 Implications

99 This novel scoring system developed by our group has implications for early detection of at-risk CHD individuals

100 for poor outcomes, both neurodevelopmental and quality of life. This subcortical paralimbic brain dysplasia score

101 is a simple tool that can be easily added to neuroradiological workflows that can lead to better outcome prediction

102 for children with CHD. Our scoring system helps us to better serve our population, allowing clinicians and

103 researchers to prognosticate highest risk individuals who will benefit from the earliest forms of intervention.

105 Introduction

106 Congenital heart disease (CHD) affects 1% of live births each year.^{1,2} As the surgical care for CHD improves, there remains lingering increased risk of poor neurodevelopmental outcomes for patients with CHD 107 108 across the lifespan. The mechanism for neurodevelopmental disabilities in non-syndromic CHD is unknown and is 109 thought to be related to fetal exposure to reduced substrate delivery/hypoxia or a genetic underpinning. Genetic 110 abnormalities are detected in approximately 50% of children with syndromic CHD, and in approximately 10% of 111 children without a recognizable clinical phenotype.³ Significant overlap is present between deleterious de novo mutations and previously reported mutations associated with neurodevelopmental disorders,⁴ suggesting that 112 113 genetic mutations that cause CHD, may also be important in the etiology of neurodevelopmental deficits.^{5,6} Smaller 114 brain volumes and dysmature brain structures are seen in neonates and fetuses with CHD before cardiac surgery, 115 suggesting that innate and/or prenatal factors may play an important role in altering brain development.⁷⁻⁹ Within 116 our current understanding of neurogenesis, there is little known about the role that deep grey and subcortical 117 regions play in mediating poor neurodevelopmental outcomes in relation to genetic alterations. Recent animal models and correlative neuropathological studies suggest that cortical dysmaturation is linked to white matter 118 abnormalities, including developmental vulnerability of the subplate in CHD.^{10,11} Recent neuroimaging studies 119 120 have documented paralimbic related subcortical morphological abnormalities in CHD patients across the 121 lifespan,¹²⁻¹⁶ but the relationship between paralimbic-related subcortical morphological abnormalities and clinical and neurodevelopmental outcomes in CHD is also unknown.¹⁷⁻²⁰ 122

123 Children with CHD are at a higher risk of developing brain dysmaturation, a generalized term encompassing abnormal and delayed development of brain macro- and microstructure²¹⁻²⁵. CHD patients are also at 124 125 risk for acquired brain injury, including infarcts and small vessel disease across lifespan as detected by 126 conventional neuroimaging studies. Clinical neuroimaging studies are also becoming more common to obtain in 127 patients during the peri-operative period based on recently published guidelines. Most conventional semiquantitative MRI scoring systems in CHD patients have exclusively focused on either acquired brain injury or 128 cortical maturation assessment, particularly in the neonatal period.²⁶⁻³³ We recently developed and validated an 129 infant semi-quantitative score that extending beyond cortical maturation and acquired brain injury to include 130 131 morphological alterations in paralimbic-related subcortical structures (including cerebellum, hippocampus, 132 olfactory bulb abnormalities), CSF-related abnormalities (including increased extra-axial CSF in frontotemporal 133 regions) and the corpus callosum known as a brain dysplasia score (BDS), informed by preclinical models of 134 CHD, specifically hypoplastic left heart syndrome (HLHS). We focused our analysis on paralimbic-related 135 subcortical structures that are known to undergo neurogenesis in early development and across the lifespan, including the olfactory bulbs, hippocampus, and cerebellum. We have recently described a similar pattern of 136 137 structural subcortical dysmaturation both in human infants with CHD and genetically relevant ciliary motion 138 dysfunction, and also in relation to preclinical models of CHD including hypoplastic left heart syndrome (HLHS).³⁴⁻⁴⁰ We have previously shown that the BDS correlates with abnormal neonatal brain white matter 139 140 connectivity patterns⁴¹ but have yet to validate this scoring system in a large dataset in relation to clinical and 141 neurodevelopmental outcomes. Here, we used quantitative structural brain magnetic resonance imaging (MRI) in 142 infants with CHD to test the hypothesis that subcortical morphological measurements could be assessed using a 143 qualitative scoring system termed brain dysplasia score (BDS) and that these subcortical structures are potential 144 predictors of not only infant cortical maturation and regional brain volumes but also are predictors of poor clinical and neurodevelopmental outcomes.12-15,21,42,43 145

146 To further validate our subcortical BDS from a genetic perspective, we leveraged the *Ohia* mouse model 147 of HLHS recovered from a large-scale mouse mutagenesis screen. In Ohia mice with HLHS, phenotypic mutations primarily arise from homozygous mutations in two genes, a chromatin modifying protein Sin3A-associated protein 148 149 130 (Sap130), and protocadherin A9 (Pcdha9), a cell adhesion protein in the a-protocadherin gene cluster.⁴⁴ 150 Importantly, both genes are known to have important roles in brain health-related outcomes. For example, the 151 clustered protocadherins provide cell surface diversity by encoding unique neuronal identity essential for patterning 152 synaptic connectivity.⁴⁵ Mice with PCDHA mutations have deficiencies in both brain connectivity and 153 neurobehavioral deficits.⁴⁶ Moreover, mutations in both PCDHA and SIN3A are associated with autism and Rett Syndrome in humans.⁴⁷⁻⁴⁹ Importantly, the SIN3A complex also contains transcription factors known to regulate 154 developmental and lifespan neurogenesis.^{50,51} Given the prominent roles of PCDHA and SIN3A in human 155 156 neurogenesis and brain development, we used the Ohia mouse model for further validation of the hypothesis that 157 the subcortical BDS could be used as a proxy of subcortical morphological and connectivity quantitative 158 measurements and predict clinical and neurodevelopmental outcomes in human CHD infants.

159 Methods

160 Ethics

161 The study was HIPAA compliant and approved by the institutional review board (IRB) of Children's Hospital Los

162 Angeles (CHLA) and Children's Hospital of Pittsburgh (CHP) of the University of Pittsburgh Medical Center

163 (UPMC) and written informed consent was obtained from each subject, except for a few patients in which MRI was

- obtained clinically, and retrospective use of the data was approved by the IRB protocol (CHLA-CCI-09-00055,
- 165 CCI-10-00235, University of Pittsburgh- 20030213,19100215, 19030204). All experiments were performed per the 166 institutional guidelines and regulations.

167 Patient Recruitment and Clinical Data Collection

168 This study is a secondary analysis of neonates with CHD (term and preterm) undergoing brain MRI scans who

169 were recruited as part of a prospective, observational study from two large medical centers, CHLA and CHP.

Neonatal CHD cases were prospectively recruited from (1) pregnancies with fetal CHD confirmed with fetal

echocardiography and (2) postnatal admissions to the cardiothoracic intensive care unit postoperatively between 2002-2016 and (3) infants with both preterm and term CHD undergoing clinically indicated brain MRI scans at

approximately term-equivalent gestational age (GA) were recruited both prospectively and retrospectively in the

peri-operative period from 2002-2017. The inclusion criterion was critical CHD defined as a heart defect expected

175 to require corrective or palliative cardiac surgery during infancy. Exclusion criteria for the CHD included

documented major chromosomal abnormalities and major congenital brain malformations. Normal referents were

recruited (1) from healthy pregnant volunteers and (2) postnatally from a normal newborn nursery. An additional

178 comparison group was included which was comprised of preterm infants without CHD who were recruited from a

high-risk NICU at the same institutions as previously published. $^{20,52-54}$ Details about the recruitment strategies have

180 been described in multiple previous publications.^{12,34,35,55-63}

181 There were 423 subjects that met the inclusion criteria for this study: 307 full term neonates (215 with CHD and 92

term controls) and 116 preterm neonates (65 with CHD born 25-36 weeks GA, and 51 preterm control patients born

183 24-36 weeks GA) (Figure 1). This is the dataset for which we performed the primary analysis of calculating a

- 184 BDS and comparing the difference between groups.
- 185

186 Research Scans

Brain MRIs for CHD infants were obtained in either the preoperative (usually between 1-7 days) or postoperative period (up to 13 weeks postnatally, but often sooner). The age range for healthy controls ranged between birth and thirteen weeks postnatally, encompassing the same range of the CHD infants. Preoperative research brain imaging was conducted when on CHD subjects when the cardiothoracic intensive care unit (CTICU) team/cardiology team

determined the patient was stable for transport to the MRI scanner. Postoperative research scan was performed at

192 less than three months of postnatal age either as an inpatient or outpatient. Most of our scans were research

193 indicated and as such no additional sedation/anesthesia was given for the scan purpose. Most of the pre-operative

scans were performed on non-intubated non-sedated patients; however, if the patient was intubated and sedated for

195 clinical reasons at the time of the scan, their clinically indicated sedation continued under care of the primary

196 CTICU. team. The post-operative scans were performed when the infant was clinically stable and thus were done

- 197 as "feed and bundle" scans without sedation. To minimize movement during imaging, infants were secured in Med-
- 198 Vac Immobilization Bag (CFI Medical) with multiple levels of ear protection, including ear plugs, MiniMuffs
- 199 (Natus Medical Incorporated), and standard headphones.

200 Clinical Scans

201 Patients in the clinically indicated brain MRI group were scanned at approximately term-equivalent GA either in

the pre- or post-operative period as previously published.⁵⁸ The post-operative scan for both preterm CHD and term

203 CHD groups was performed at least within 52 weeks corrected postconceptional age.

204 Neonatal Brain MRI Protocol

MRI studies were acquired: (1) GE 1.5T (Signa LX, GE Healthcare, Milwaukee, WI) MR system using a custombuilt neonatal transmit-receive head coil, (2) Philips 3T Achieva MR System (Ver. 3.2.1.1) using standard 8-

- 207 channel SENSE head coil; and (3) Siemens Skyra 3T scanner using a 20-channel coil. Conventional imaging
- 208 studies were acquired with the MRS studies and included a 3D coronal SPGR sequence (TE=6 ms; TR=25 ms.
- 209 FOV=18 cm; matrix= 256×160 ; slice thickness 1.5 mm, spacing 0 mm) or axial and sagittal T1-weighted FLAIR
- 210 sequences (TE=7.4, TR=2100; TI=750; FOV=20 cm; Matrix= 256×160), axial T2-weighted FSE sequence 211
- (TE=85ms, TR=5000ms, FOV=20 cm, matrix = 320×160 or 256×128) and a diffusion-weighted sequence 212 (TE=80; TR=10000; FOV=22 cm; Matrix = 128×128 ; slice thickness =4.5 mm, spacing 0 mm). The 3D T1-
- 213 weighted, T2-weighted, and diffusion-weighted images were reviewed by two pediatric neuroradiologists for
- 214 evidence of punctate white matter lesion, hypoxic-ischemic injury, acute focal infarction, and hemorrhage as
- 215 previously described and were used to construct dichotomized and composite brain injury scores.⁶⁴

216 Subcortical brain dysplasia MRI score (BDS) derivation

- 217 Our development of the subcortical based BDS has been derived from observations from both preclinical mouse
- CHD mutants and human CHD infants from recent studies from our group.^{21,22,36,39,65-67} The evaluation for brain 218
- 219 dysplasia in our human CHD population is conducted by examining the following structures: cerebellar
- 220 hemispheres (both left and right together), cerebellar vermis, right olfactory bulb, right olfactory sulcus, left
- 221 olfactory bulb, left olfactory sulcus, hippocampus, choroid plexus, brain stem, corpus callosum, and supratentorial
- 222 extra-axial fluid. Supplemental Figure 1 depicts a visualization of how the BDS was calculated. Except for the 223
- supratentorial extra-axial fluid, each of the structures listed were evaluated on whether they appear normal or abnormal. For cerebellar hemispheres and cerebellar vermis, they were scored for hypoplasia (small volume) and
- 224
- 225 dysplasia (abnormal shape). Likewise, the olfactory bulbs and sulci were evaluated as separate structures for 226 purposes of scoring. Based on the finding, a binary number score is given for each structure, with a score of 0 227 assigned for normal and a score of 1 for abnormal. For olfactory bulbs and sulci, both hypoplastic and absent 228 findings are treated as abnormal and given a score of 1. For supratentorial extra-axial fluid, the structural features 229 demonstrate different gradations of abnormality - none, mild, moderate, or severe fluid accumulation - and thus 230 successively higher integer scores are assigned as the severity of abnormality becomes greater. The integer scores 231 for each of the structures were then summed to create the BDS with "olfactory correction" which treats both absent 232 and hypoplastic olfactory abnormalities as one score point, thus making the weighting of the olfactory system in
- 233 line with cerebellum and hippocampus. Higher BDS values can be thought of as having a "worse" score as subjects
- 234 had more abnormalities present. A subset of cases was reviewed by two raters to validate the scoring.

235 Similar to our BDS, a brain injury score was calculated for each human subject. The composite brain injury score 236 consisted of four criteria with each criterion being scored as a 1 if present in the subject. The four criteria were 237 hemorrhage, infarct, hypoxic ischemic injury, and periventricular white matter injury (PWMI). A dichotomized 238 version was also calculated for each individual and was scored as a 1 or 0. If the original brain injury score was 239 greater than 0, then the composite score was a 1; otherwise, the score was a 0. A visual depiction of the brain injury 240 scores can be found in Supplemental Figure 2.

241

242 Structural Co-variate Analysis: Cortical Maturation Score and Regional Brain Volumetric Analysis

243 We correlated BDS with a classic cortical Total Maturation Score (TMS) and regional brain volumes. A cortical 244 TMS was calculated for all subjects with brain MRI included in this analysis. A subset of the full cohort (term 245 controls and CHD scanned at 3T imaging, n=105) underwent cerebral regional volumetric segmentation for 246 structural co-variate analysis. To determine the relationship between our qualitative BDS and quantitative regional 247 morphological dysmaturation, we performed regional brain morphometric techniques including volumetric 248 segmentation of total intracranial cerebral spinal fluid (CSF), cortical grey matter, cortical white matter, deep grey 249 nuclei, brainstem, and cerebellum using a neonatal and infant brain segmentation age-specific atlas. We further 250 segmented total intracranial CSF into three compartments: supratentorial extra-axial CSF, infratentorial extra-axial 251 CSF and intraventricular CSF. Our group used the above age-specific atlas to build a semi-automated brain 252 parcellation pipeline for use in neonates and young infants (Supplemental Figure 3). The automated processing 253 pipeline which was previously described in by our group,³⁵ was developed using Nipype and interfaces with several 254 image registration algorithms using age-appropriate neonatal/infant templates to accommodate different post-255 conceptional ages in the patient cohort. Our methodology for volumetric segmentation of neonatal brain has been 256 previously described.^{68,69} We further refined this methodology for the current study because of the wide range of 257 post-conceptional ages of neuroimaging studies and the resulting need to use a range of neonatal and infant age-258 appropriate templates. We also performed validation experiments to ensure optimal performance with this

259 neonatal/infant CHD cohort with mild brain dysplasia. We processed each patient's T1 and T2 volumetric images in 260 parallel to optimize registration parameters uniquely to each tissue contrast. First, the images were cropped, and 261 brain extracted using FSL BET. The volumetric images (T1 and T2 separately) were then biasfield corrected using 262 FSL's FAST segmentation. We then registered the bias-field corrected images to the tissue contrast specific and post-conceptional age matched template, created by Serag et. al,⁷⁰ using a non-linear registration from Advanced 263 Normalization Tools (ANTs). The output transformations were inversed and applied to the template space tissue 264 265 probability maps provided with the neonatal atlas. This transformation results in subject-space tissue probability 266 maps. We calculated tissue volumes by thresholding the partial volume maps at a visually acceptable lower bound 267 and extracting the volume from the binarized mask. The subject-space segmentations were manually checked for 268 accuracy by an expert pediatric neuroradiologist (AP) blinded to patient diagnosis.

269

270 Clinical Risk Factor Analysis

271 We correlated BDS with clinical risk factors. Analysis of clinical risk factors included a subset of subjects with 272 critical CHD who required corrective or palliative cardiac surgery within the first month of life who were 273 prospectively enrolled for pre and postoperative brain MRI scans from 2009-2016. Two hundred ninety-one 274 subjects were prospectively enrolled from June 2009 to October 2016. Of these subjects, 158 met exclusion criteria 275 including 57 with no MRI done, 38 due to prematurity, 38 passed the age threshold, 11 expired preoperatively, 10 276 had no neonatal surgery and 4 had a postnatal major genetic diagnosis. Of the 133 term CHD infants with brain 277 MRI meeting inclusion criteria, 90 subjects had sufficient imaging quality for structural analysis and clinical risk 278 factor data collected, comprised the study group for this analysis. Subjects that had a known major chromosomal 279 abnormality, were premature (<=36 weeks of age), died prior to MRI or did not require neonatal cardiac surgery 280 were excluded in this analysis. Clinical data was collected from the electronic medical records and included 18 281 patient-specific and 9 preoperative variables associated with preoperative scan and 6 intra-operative (e.g., 282 cardiopulmonary bypass, deep hypothermic circulatory arrest times) and 12 postoperative variables associated with postoperative scan, as described previously.^{59,71} CHD lesions were classified in several ways (not mutually 283 284 exclusive) including postnatal cyanosis, presence of aortic arch obstruction, single vs. double ventricles, d-285 transposition of the great arteries, conotruncal defects, heterotaxy, whether the lesion alters fetal cerebral substrate 286 delivery and severity of this alteration (normal, altered, severely altered).

287 Feeding Outcomes

288 We correlated the BDS with feeding outcomes. The feeding outcome study group consisted of term infants with 289 CHD who had neonatal brain MRI with brain dysplasia score between 2003-2015, enrolled both prospectively for 290 research MRI and retrospectively after clinical MRI, at CHLA and CHP. Subjects with major gastrointestinal 291 anomalies or surgeries, a diagnosis of CHARGE syndrome, death within the first 30 days of life, or death prior to 292 initiation of feeds were excluded from the feeding analysis. For the feeding study, we evaluated 177 term infants 293 with CHD who had MRI that were used to calculate BDS as described above. Of those, 32 were excluded 294 including 14 with major gastrointestinal anomalies or surgeries, 1 with brain anomaly, 6 with CHARGE syndrome, 295 and 11 that died in the first 30 days or prior to initiation of feeds. Therefore, the feeding analysis group consisted of 296 145 subjects of which 81 were from CHLA and 64 from CHP. The inpatient medical records were assessed for the 297 following feeding-related variables: presence of dysphagia, aspiration, gastroesophageal reflux, gastrointestinal 298 dysmotility, intestinal malrotation, vocal cord paralysis, use of enteral tube feeding (including nasogastric, 299 nasojejunal, or surgically placed gastric or jejunal tubes), lack of oral feeding prior to neonatal hospital discharge,

300 and length of neonatal hospitalization.

301 Neurodevelopmental Outcomes

302 For neurodevelopmental outcomes assessment, Bayley Scales of Infant and Toddler Development or Battelle

303 Developmental Inventory were completed by a licensed psychologist in a subset of patients. A total of 90 subjects

304 (CHLA n=32, CHP n=58) had early neurodevelopmental outcome data obtained between 15 to 18 months postnatal

305 age. The standard score for each developmental domain (motor, language/communication, cognitive, and

306 social/emotional) was evaluated. Developmental delay was defined as a standard score greater than 2 standard

307 deviations below the mean in 1 developmental domain. Global developmental delay was defined as a standard 308 score greater than 2 standard deviations below the mean in 2 or more developmental domains. The following

score greater than 2 standard deviations below the mean in 2 or more developmental domains. The following
 criteria was used: Average= Standard Score 90 to 109 (25th to 74th percentile); Low Average= Standard Score 80 to

310 89 (9th to 24th percentile); Below Average= (2nd to 8th percentile); Exceptionally low= (<2nd percentile). The data 311 was then dichotomized to ves/no for (1) developmental delay, (2) global developmental delay, and (3) below

312 average for each subject to facilitate harmonization between the two different test exams across both sites.

313 Mouse Screen Analysis

A retrospective analysis was carried out on the mouse lines described by Li et al.⁷² In brief, a forward recessive 314 315 mouse screen was carried out using N-ethyl-N-Nitrosourea in which 3700 mouse lines, defined by G1 sire, were 316 screened for defects. Defect screening was completed through ultrasound scanning, micro-computed tomography 317 (CT), micro-magnetic resonance imaging (MRI) and visual inspection of G3 offspring. Resulting mutant cardiac 318 phenotypes were confirmed through necropsy, or histopathologic analysis. Further analysis was completed 319 examining the craniofacial and gross brain abnormalities discovered within the screen. Lines in which a mutant was 320 recovered in the original screen were analyzed for both craniofacial and gross brain abnormality. Consistent 321 phenotype in at least three mice was required for a line to be considered abnormal with a craniofacial or brain 322 abnormality. An additional mouse model which recapitulates the phenotype of Joubert syndrome was analyzed 323 prior to any analysis on the main Ohia line to validate method and findings. The mouse model was previously validated by Damerla et al.⁷³ This Joubert syndrome mouse mode is colloquially called Heart Under Glass (*Hug*) 324 325 and contains a S235P missense mutation in Jbts17. The Hug mice recapitulate the brain phenotype of Joubert 326 syndrome presenting with decreased number of cerebellar fissures.

327 Episcopic Confocal Microscopy (ECM)

328 Head samples were removed following necropsy and fixed in 4% PFA solution for a minimum of 72 hours. After

fixation, samples were prepared for ECM via three graded ethanol baths of 10%, 20%, and 40% overnight at room

temperature. Samples were then transferred to a Sakura Tissue Tek VIP 5 Tissue Processor where they were

dehydrated using increasing percentages of warmed ethanol baths and eventually perfused with paraffin wax.

332 Samples were embedded in paraffin blocks to be sectioned coronally. 3D reconstructed images stacks were used for 333 brain scoring and volumetric analysis. A diagram for the ECM workflow can be found in Supplemental Figure 4.

334 Mouse Brain Dysplasia Scoring

A group of three reviewers reviewed 84 cases consisting of 69 Ohia, five CRISPR/CAS9, and 10 wild type

336 samples. Reviewers came to a consensus for each structure scored. In total seven structures were included the

337 mouse brain scoring including hippocampus, cerebellum, cerebrum, left and right olfactory bulbs, brain stem, and

midbrain. Hippocampus, cerebellum, and both olfactory bulbs were scored for aplasia, hypoplasia, and dysplasia.

Cerebrum, brain stem and midbrain were scored for hypoplasia and dysplasia only. Each instance of abnormality
 received a binary score of zero or one. Brain Dysplasia Score (BDS) was a sum of each area of the brain. Two

other BDS metrics were calculated, one being a binary scoring of any cerebellar or hippocampal abnormalities and

342 the another being a binary score if any abnormality was present in the sample at all. Cerebellar folds were counted

343 using a sagittal view in the middle slice of the brain.

344 Mouse Brain Segmentation

345 Tiff images were converted to NIFTI images using ITK-Snap and FSL. Images were down sampled 4x using 346 FMIRB's Linear Registration Tool (FLIRT). Resulting images were manually segmented into 16 discreet structures 347 using ITK-Snap. Structures segmented included right hippocampus, right olfactory bulb, right subcortical area, 348 right cortex, intracranial space, midbrain, left hippocampus, left olfactory bulb, left subcortical area, left cortex, 349 extra-axial space, cerebellum, pons, medulla, hypothalamus, and choroid plexus. Due to the required processing 350 methods for ECM, CSF is removed from the brain and replaced with paraffin wax. The space voided of CSF has 351 been labeled as intracranial space and extra-axial space. Structures above the tentorium were combined to form a 352 supratentorial volume and an infratentorial volume was also calculated. Infratentorial volumes consisted of the 353 pons, medulla, and cerebellum, while the supratentorial volumes were composed of the hippocampus,

354 hypothalamus, olfactory bulbs, subcortical areas, cortex, and midbrain.

355 Genotype Analysis

- We explored the relationship of Sap130/ Pcdha9 genotype and brain morphology in the mouse modeling. When
- comparing the risk stemming from the BDS for animals from the Ohia line, different genotypes were grouped into
- 6 distinct groups. Group A: *Sap130*(m/m) and *Pcdha9*(m/m), Group B: *Sap130*(m/m) and *Pcdha9*(m/+), Group C:

Sap130(m/m) and Pcdha9(+/+), Group D: Sap130(m/+) and Pcdha9(m/m), Group E: Sap130(+/+) and Pcdha9(m/m), and lastly, Group F: Sap130(m/+) or (+/+) and Pcdha9(m/+) or (+/+).

361 Mouse Genotype Groupings and Comparisons

362 For greater power in subsequent analysis, mice with similar genotypes were pooled into Groups. Group ABC 363 consisted of mice which were homozygous mutant for Sap130 (m/m), irrespective of their Pcdha9 genotype. An 364 additional Group, AB, contained mice which were homozygous mutant for Sap130 (m/m), and either homozygous 365 mutant or heterozygous for *Pcdha9* (m/*). To study the effect of homozygous mutations in the *Sap130* gene, 366 Group ABC was compared against wildtype animals. Group ABC was then compared against Group F. Group F 367 can only be heterozygous for Sap130 and Pcdha9, so any effect of the homozygous mutant Sap130 alleles would 368 be removed in this group. This pairing should show effects of the homozygous Sap130 mutation more concretely. 369 To assess if any of the effect is coming from the *Pcdha9* genotype, Group AB was then compared to F. Group AB 370 differs from Group ABC by removing samples that contained, wildtype *Pcdha9* genotyped animals. If *Pcdha9* is 371 partially, or in large part, responsible for the observed phenotype, removing wildtype Pcdha9 samples from the 372 ABC Group should increase incidence and effects should become more significant. To further isolate the effect of 373 Sap130, Group A was compared against Group C with the difference between groups being homozygous mutant 374 Pcdha9 (Group A) vs wildtype (Group C). Lastly, Group B was compared against Group D. Group B is 375 homozygous Sap130 and heterozygous Pcdha9, and Group D is the opposite, Sap130 heterozygous, and Pcdha9 376 homozygous mutant. If either homozygous gene is more significant than the other, the effect could be seen within 377 this comparison. 378

379 RNAseq Analysis

RNA was isolated from brain tissue samples of 4 *Ohia* mutant animals and 5 littermate controls at embryonic day
 E13.5-E14.5, libraries were constructed and sequenced on the Illumina HiSeq 2000 platform (BGI Americas), and
 differential gene expression analysis was conducted as previously described (Gabriel et al. Biorxiv paper). The online
 Database for Annotation, Visualization, and Integrated Discovery (DAVID) was used to perform gene ontology (GO)
 functional enrichment analysis.

385

386 Statistical Analyses for Human Studies

Primary analysis: SAS statistical software was used to carry out human statistical analysis. Our primary analysis
 compared the derived BDS between neonates with CHD and controls. This analysis was performed using

389 multivariate regression and three major co-variates were included in the model: gender, postconceptional age

390 (PCA=gestational age plus postnatal age), time of MRI scan timing of scan relative to cardiac surgery (pre- vs post-

- operative). Multi-variate regression with false discovery rate (FDR) correction was used, to correct for multiple
- comparisons. The FDR is one way of conceptualizing the rate of type 1 errors in null hypothesis testing when
 conducting multiple comparisons. Whether BDS is association with sex difference, GA, or PCA was assessed in
- 394 the entire study cohort.

Secondary analysis: Secondary analysis was repeated within the CHD only group, with birthweight and the
 presence of genetic abnormality included as additional comparisons with BDS. Furthermore, whether pre- or post operative and pre-term or term status correlated with BDS was also analyzed within the CHD group. As an

- 398 additional secondary analysis, within the CHD group, BDS was compared to the presence of various injuries and
- 399 cortical maturation features. Additional secondary analyses including correlation of BDS with feeding data and
- 400 neurodevelopmental outcome which consisted of linear and logistic regression with false discovery rate (FDR)
- 401 correction for multiple comparisons; FDR-adjusted p-value <0.05 was considered significant.

402 Statistical Analyses for Mouse Studies

403 Volumetric analysis of mouse individual structures was carried out using SAS statistical software. Both raw and

404 normalized by total brain volume values were compared in any models generated. We completed an ad hoc

405 analysis to delineate the relationship between BDS and regional brain volumes, clinical risk factor and heart lesion

406 subtypes on our primary outcome measures. Clinical variables were compared using a three-way ANCOVA

407 (analysis of covariance) between wild-type, *Ohia*, and *Hug* animals. We then compared each of the groups

408 mentioned above to each other using pairwise T-tests.

409 Role of Funders

410 Funding sources were not involved in patient recruitment, data collection, analysis, or formation of the manuscript.

411 All work was original and completed by the authors without interaction by the funding sources.

412 Results

413 Comparison of Brain Injury/Cortical Maturation Score (TMS) between CHD and Control Cohorts:

414 The preterm CHD and term CHD cohort demonstrated increased incidence of brain injury compared to their

415 gestational-aged, matched controls. Specifically, the CHD preterm cohort demonstrated increased incidence of

focal infarcts (p = 0.0295) and punctate white matter lesions (p = 0.0231) compared to the preterm control cohort.

417 The term CHD cohort demonstrated increased rates of hemorrhage (p = 0.0284), focal infarct (p = 0.0035),

418 punctate white matter lesions (p < 0.001), dichotomized injury composite score (p < 0.001), and injury composite

- 419 score (p < 0.001) compared to the term control cohort (Supplemental Table 1).
- 420 When comparing the categories of the cortical maturation score (TMS), the term CHD cohort had widespread

421 reduced cortical maturation (in all cortical lobes except occipital) compared to term control cohort, while the

422 preterm CHD only differed from preterm controls in the myelination category (Supplemental Table 2).

423 Derivation of Human BDS in Human Infant CHD:

424 There was a high incidence of olfactory, hippocampal, and cerebellar abnormalities in the preterm and term CHD

425 cohorts compared to both preterm and term control cohorts respectively (Table 1). Within the univariate analyses,

there was no significant correlation between BDS and sex, GA, or PCA within the entire study cohort (Table 2A).

427 Within the CHD cohort, there was no correlation between BDS and pre/postoperative status, preterm/term status, or

birth weight. Higher BDS in the CHD cohort was correlated with known genetic abnormalities (Table 2B), which

429 remained a significant association in the multivariable analysis (Table 2C). BDS was highly correlated with cortical

430 immaturity by cortical maturation scores including frontal cortex (p < 0.0001), insular cortex (p < 0.0001), and 431 cortical folding (p = 0.0016), even after controlling for PCA at the scan (Table 3). There was no significant

431 correlation between BDS and any categories of brain injury (Table 3). Within a subset of cases the inter-rater

432 reliability was calculated and resulted in reviewers one and two receiving high scores for most metrics included in

the BDS calculation. Notable exceptions were for cortical folding (kappa = 0.18, 0.00), myelination (kappa = 0.35,

435 0.02), supratentorial extra-axial fluid (kappa = 0.35, 0.05), and germinal matrix (kappa = 0.48, 0.00). Other values

436 for Cohen's kappa measure for the BDS can be found in Supplemental Table 3.

437 Human Infant BDS and Regional Cerebral Volumes:

Higher BDS correlated with smaller left and total cerebellar volume, smaller deep grey matter and brain stem
volumes, and increased infra-ventricular and supra-tentorial CSF volumes in the entire sample (term CHD and term
control cohorts combined) (Table 4). Increased BDS was more strongly correlated with reduced cerebellar volume,
reduced cortical volumes, and increased CSF volume in the term CHD cohort compared to the term control cohort

442 (Table 4).

443 Human Infant BDS and Clinical Risk Factors:

444 When assessed against clinical risk factors in term CHD infants, the BDS did not correlate with birth factors, 445 anthropomorphic data, cardiac lesion type, or intraoperative factors. (Supplemental Table 4A-D). The BDS did

446 correlate with age of under 7 days at surgery (p<0.048, Supplemental Table 4B), increased length of hospitalization

447 (p<0.0447, Supplemental Table 4D), and need for G-tube placement during the neonatal hospital stay (p<0.01,

Supplemental Table 4D). Of note, we found no correlation between BDS and MRI field strength/scanner type(Supplemental Table 5).

450 Human Infant BDS and Feeding Outcomes:

451 Lack of oral feeding before neonatal hospital discharge was associated with multiple morphological abnormalities

452 of the components of the BDS including cerebellar hemispheres and vermis, hippocampus, bilateral olfactory bulbs

and olfactory sulci, corpus callosum, increased supratentorial extra-axial fluid, as well as total increased BDS.
 Hospital length of stay was associated with dysplasia of the cerebellar hemispheres and vermis, hippocampus,

454 Hospital length of stay was associated with dysplasia of the cerebenal hemispheres and vernis, inprocampus, 455 choroid plexus, brainstem, increased supratentorial axial fluid, and BDS. A diagnosis of dysphasia was associated

456 with dysplasia of the brain stem (p=0.001). Gastrointestinal dysmotility, aspiration, gastroesophageal reflux,

457 malrotation, and vocal cord paralysis demonstrated no significant associations with brain dysplasia. Figure 2 panels

458 A-D show some of the variations in hippocampal anatomy seen in the human population compared against that

459 seen in the mouse in panels E and F. Figure 3 demonstrates olfactory bulb abnormalities in human infant CHD vs

460 control (A/C) and the mouse model (B/D). Figure 4 demonstrates cerebellar abnormalities in the human infant

461 CHD vs controls (A-top) and the mouse model (A-bottom).

462 Human Infant BDS and Neurodevelopmental Outcomes:

- 463 Increased BDS correlated with developmental delay in at least one domain including motor, cognitive,
- 464 language/communication, or social/emotional (p<0.02), and specifically with poor expressive language
- development (p < 0.016) in a subset of the original sample tested at 15-18 months of age (n=90), given in Table 6.

466 Mouse CHD Screen Results

From the original mouse screen for CHD, 3208 mouse pedigrees were screened, and 390 (12.16%) mutant lines were discovered. Of the 390 mutant lines, 214/390 (54.87%) had some form of craniofacial anomaly and 69/390 (17.69%) lines had a severe brain anomaly. Within those categories, craniofacial and brain anomalies, 174/214

470 (81.31%) and 62/69 (89.86%) had co-occurrence of CHD, respectively. Supplemental Figure 5 demonstrates some

- 471 of the craniofacial abnormalities seen during the screening. 68 lines contained features of both types of anomalies,
- and of those 68 lines, 61 also exhibited CHD. A summary of the results can be seen in Figure 5

473 Hug Model Mouse ECM Validation

To validate the ECM method, a mouse model, colloquially called Heart Under Glass or Hug, for Joubert syndrome

- with a S235P missense mutation in Jbts17 was analyzed prior to analysis of Ohia mice. Joubert syndrome is a
- 476 ciliopathy associated with cerebellar abnormalities and other birth defects. In addition, Hug mice also had higher
- 477 incidences of BDS (p = 0.0161). and specifically, in the cerebellum-hippocampus dichotomized BDS (p = 0.0154). 478 Compared to wildtype mice, Hug mice showed an overall increase in cerebellar abnormalities (p < 0.001) and a
- 478 Compared to whatype nice, Hug nice showed an overall increase in cerebenal 479 decrease in the number of cerebellar fissures (p=0.0023).

480 Ohia Mouse Model Brain Dysplasia Scoring

481 ECM analysis was completed on 69 Ohia mutant neonatal mice. There was an increase in the BDS in the Ohia 482 group compared to the wildtype group (p < 0.001) (Table 7). With regards to individual subcortical abnormalities 483 (which make up the composition of the BDS), the cerebellum showed the highest incidence of abnormality with 484 dysplasia being present in 49/67 (73.13%) of animals scored and was highly significant compared to control 485 animals (p < 0.001). Ohia mutants also showed a decrease in the number of cerebellar fissures (p < 0.001) 486 compared to the wild type group. The Ohia mutants also showed an increase in incidence of hippocampal dysplasia 487 (p = 0.002), cerebral dysplasia (p = 0.003), left olfactory bulb aplasia (p = 0.024), left olfactory bulb any 488 abnormality (p = 0.006), right olfactory bulb aplasia (p = 0.02), and right olfactory bulb any abnormality (p = 0.02) 489 0.007) (Table 7). Supplemental Figure 6 demonstrates some of the common phenotypes seen in Ohia mice. 490 Findings of aplasia, hypoplasia or dysplasia were common in the olfactory bulb, cerebellum, and/or hippocampus.

Additionally holoprosencephaly was a coincidental finding in Ohia mice with 42/69 (60.9%) showing some signs
 of holoprosencephaly. Supplemental Figure 7 shows Ohia animals and two examples of the holoprosencephaly

493 observed in this population.

494 Ohia Brain Dysplasia Scoring within CHD Subgroupings

To examine the relationship between CHD lesions and brain dysmaturation, the co-occurrence of different brain anomalies and any form of CHD was compared. We compared within the Ohia cohort looking at BDS and cerebellar fissures and found that the presence of CHD increased the BDS and reduced cerebellar fissures (p- < 0.001) (Table 8). Looking at other forms of cardiac sub-lesions, there was no significant differences between BDS and cerebellar folds (Table 8).

- 500 In Ohia animals there were 10 brain structures which showed an increased incidence of abnormalities in animals
- with CHD. Those structures included hippocampal dysplasia (p = 0.043), cerebral hypoplasia (p = 0.008), cerebral
- 502 dysplasia (p < 0.001), cerebellar dysplasia (p < 0.001), left olfactory bulb aplasia (p < 0.001), left olfactory bulb
- any abnormality (p < 0.001), right olfactory bulb aplasia (p < 0.001), right olfactory bulb any abnormality (p < 0.001).
- 504 0.001), brainstem dysplasia (p = 0.016), and midbrain dysplasia (p = 0.0062) (Supplemental Table 6A). Comparing
- single versus biventricular morphology, defects were more common in the cerebellum in double ventricular mice (p
- 506 < 0.001) (Supplemental Table 6A). When comparing conotruncal vs non-conotruncal defects, mice with
- 507 conotruncal defects showed an increased in the occurrence of hypoplasia in the cerebrum (p = 0.037)
- 508 (Supplemental Table 6B) Within cyanotic vs acyanotic cardiac defects, mice with acyanotic defects showed

- 509 increases in the incidence of left olfactory bulb hypoplasia (p = 0.018) and any defect in the cerebellum (p = 0.037).
- 510 Lastly, looking at mice with and without arch obstructions, mice with arch obstruction showed an increase in the
- 511 occurrence of any defect in the cerebellum (p = 0.048) (Supplemental Table 6B).

512 Ohia Mouse Model Regional Brain Volumes

- 513 Ohia mutants demonstrated a significant decrease in raw (non-normalized) volumes of the right subcortical (p =
- 514 0.044), left subcortical (p = 0.041), cerebellar (p = 0.005) and supratentorial volume (p = 0.037) volumes (non-
- normalized) compared to wild type control. Ohia mutants also demonstrated an increase in the intraventricular
- 516 volume (p = 0.009) compared to wild type controls (Supplemental Table 7.
- 517 Normalizing volumes to total brain volume showed Ohia animals also exhibited a significant increase in medullary
- (p = 0.024) and intraventricular normalized volume (normalized to total brain volumes). (p = 0.015). Ohia animals
- also demonstrated a decrease in normalized supratentorial volumes (p = 0.01) compared to wild type controls
- 520 (Supplemental Table 7).

521 Ohia Mouse Model Regional Brain Volumes within CHD Subgroupings

- 522 There were no differences in raw (non-normalized) volumes between Ohia mice with and without CHD. Looking at 523 single versus biventricular morphology, mice with biventricular heart defects showed increases in the volumes of
- the right subcortical areas (p = 0.006), left subcortical area (p = 0.036), and the pons (p = 0.024) (Supplemental
- 525 Table 8a). Comparing conotruncal against non-conotruncal heart defects, mice with conotruncal defects showed an
- increased in the right subcortical area (p = 0.043) (Supplemental Table 8b). Mice with acyanotic defects
- 527 demonstrated an increase in the volume of the left hippocampus (p = 0.044) (Supplemental Table 8b). There were so differences in volume noticed between mice with and without arch obstructions.
- 529 After normalizing raw volumes to total brain volume different regions showed significance between groups.
- 530 Between CHD and non-CHD Ohia mice, Ohia mice with CHD showed increased volumes in the right cortex (p =
- 531 0.026), midbrain (p = 0.044) and cerebellum (p = 0.044). Comparing normalized volumes within single and
- 532 biventricular groupings found that single ventricular morphology heart defect mice had increased choroid plexus
- volumes (p < 0.001). (Supplemental Table 9a). There were no significant findings looking between groups of
- conotruncal vs non-conotruncal, cyanotic vs acyanotic, or arch obstruction vs no arch obstruction (SupplementalTable 9b).

536 Ohia Mouse Model Brain Dysplasia Scoring within Genotype Subgroupings

- 537 Comparing genotypes within the Ohia cohort, samples were first grouped based on genotypes. The two groups with 538 the most samples were group A which consisted of Sap130 and Pcdha9 double mutants and group F consisted of 539 animals which did not have a Sap130 or Pcdha9 homozygous mutant genotype (Table 9). Both groups showed high 540 incidence rates of olfactory bulb, cerebellar, hippocampal, and brainstem abnormalities (Table 9). Using Group 541 ABC mentioned in the Mouse Genotype Groupings section in the methods, values of hippocampus and cerebellar 542 BDS (p < 0.001) and BDS total (all structures) were greater (p < 0.001) in Group ABC compared to wildtype 543 (Table 10).
- 544 Within the different genotype groups there were various findings. Groups A and B had 19/24 (79.17%) and 6/8
- (75%) of mice exhibiting some form of holoprosencephaly. Additionally, those groups had the high rates of CHD
 and the various subtypes of CHD (i.e., conotruncal, single ventricular morphology, cyanotic defects, and arch
 obstructions) (Supplemental Table 10.
- 548 When comparing ABC vs WT, to determine homozygous Sap130 mutation difference compared to controls, 10
- 549 structures studied showed greater incidence values in ABC compared to wildtype. Those structures included
- 550 dysplastic hippocampus (p < 0.001), hypoplastic cerebrum (p = 0.40), dysplastic cerebrum (p < 0.001), dysplastic
- 551 cerebellum (p < 0.001), aplastic left olfactory bulb (p = 0.001), combination of left olfactory bulb (p < 0.001),
- aplastic right olfactory bulb (p = 0.001), combination of right olfactory bulb (p = <0.001), dysplastic brainstem (p = 0.001), dysp
- 553 0.037), and the dichotomized BDS ($p = \langle 0.001 \rangle$ (Supplemental Table 7a).
- 554 Comparing groups ABC vs. F to determine homozygous Sap130 mutation difference compared to no homozygous
- 555 mutation in either gene (at most hetero or WT for either mutation), hippocampal and cerebellar BDS was different
- between groups with ABC, a higher incidence (p = 0.008) (Table 10). Eight structures had significantly increased
- incidence in group ABC compared to F. Structures included hypoplastic cerebrum (p = 0.021), dysplastic cerebrum

- (p = 0.016), dysplastic cerebellum (p < 0.001), aplastic left olfactory bulb (p = 0.035), combination of left olfactory
- bulb (p = 0.010), aplastic right olfactory bulb (p = 0.022), combination of right olfactory bulb (p = 0.018), and dichotomized BDS (p = 0.021). Additionally, the ABC group had an increased value for the hippocampus and sembally BDS (p = 0.008) (Symplemental Table 7a)
- 561 cerebellum BDS (p = 0.008) (Supplemental Table 7a).

562 In comparing groups AB vs. F, (homozygous Sap 130 mutation and homo/heteroPCDHA9 vs no hippocampal and 563 cerebellar BDS was significantly different between groups (p 0.021) (Table 10). Seven structures showed 564 significant differences in the rate of abnormalities; structures included hypoplastic cerebrum (p = 0.035), dysplastic 565 cerebrum (p = 0.019), dysplastic cerebellum (p = 0.001), aplastic left olfactory bulb (p-value = 0.039), combination 566 of left olfactory bulb (p = 0.023), aplastic right olfactory bulb (p = 0.023), and combination of right olfactory bulb 567 (p = 0.023) (Supplemental Table 7b). Comparing groups A vs C, only 2 structures were found significant. Those 568 structures were dysplastic brainstem (p = 0.028) and dysplastic midbrain. (p = 0.042) (Supplemental Table 7b). 569 Comparing groups B vs D, only aplastic hippocampus (p 0.029) and any defect in hippocampus (p = 0.014) were 570 found to be significant (Supplemental Table 7c).

571 Ohia Mouse Model Regional Brain Volumes within Genotype Subgroupings

Looking at volumes for brain regions between genotype groups, in group ABC vs wild type, six areas were found
 to be significantly different with mice in group ABC having reduced volumes including the right subcortical area (p

- 574 = 0.006), right cortex (p = 0.047), left subcortical area (p = 0.007), cerebellum (p-value = 0.003), supratentorial
- volume (p = 0.013), and total brain volume (p = 0.028) (Supplemental Table 11a).
- 576 In group ABC vs F, mice in group ABC showed significant volume reductions in eight structures. Structures
- 577 included right hippocampus (p-value = 0.041), right subcortical areas (p = 0.050), right cortex (p = 0.016), left
- 578 hippocampus (p-value = 0.031), left olfactory bulb (p = 0.048), left cortex (p = 0.022), supratentorial volume (p-
- value = 0.018), and total brain volume (p = 0.022) (Supplemental Table 11a). Similarly comparing groups AB vs.
- 580 F, mice in group AB showed significant reductions in volumes in eight structures. Differences occurred between 581 right him segment (-0.021) right ach series (-0.022) right sector (-0.020) left him segment (-0.02
- right hippocampus (= 0.021), right subcortical areas (p-value = 0.023), right cortex (p = 0.029), left hippocampus (p-value = 0.024), left subcortical areas (p = 0.038), left cortex (p = 0.029), supratentorial volume (p = 0.014) and
- (p-value = 0.024), left subcontear areas (p=0.038), left cortex (p=0.029), supratementative (p=0.014) and total brain volume (p=0.014) (Supplemental Table 11b). Lastly, comparing group A vs C, animals in group A
- solution for the showed significant reductions in four areas including the right subcortical area (p = 0.022), left sub
- =0.034), infratentorial volume (p =0.047), total brain volume (p =0.049) (Supplemental Table 11b).
- 586 After normalizing raw volumes to total brain volume, multiple brain regions showed significant differences
- between groupings. The ABC group demonstrated increased volume of the midbrain (p = 0.027) and medulla (p = 0.027)
- 0.005) and decreased volume of the right olfactory bulb (p = 0.037) and supratentorial region (p = 0.009) compared
- to the wild type groups (Supplemental Table 12a). The ABC group demonstrated significant increases in volume in
- 590 three areas including the cerebellum (p = 0.010), medulla (p = 0.043), and choroid plexus (p = 0.012) compared to
- the F group. Additionally, the right cortex volume was reduced in animals in group ABC compared to F (p = 0.028) (Supplemental Table 12a).
- 593 Comparing groups AB vs F, mice in group AB demonstrated three structures with significant increases in volume 594 including the cerebellum (p = 0.012), pons (p = 0.049), and choroid plexus (p = 0.029). There were no significant 595 differences between groups A vs C and B vs D (Supplemental Table 12b).

596 Mouse CHD/Ohia RNA-seq

- 597 RNA-seq transcriptome profiling in term Ohia brains showed changes in genes involved in learning and memory,
- 598 feeding behaviors, neuronal differentiation, and synaptic transport (Figure 6) Sap130 chromatin
- immunoprecipitation sequencing (CHIP-seq) looking at targets associated with Sap130 in brain tissue revealed a
- total of 644 genes being associated with cardiac and brain associated genes. Of those 644 genes, 106 and 324 were
- 601 cardiac and brain genes, respectively, with the remaining 214 genes being associated with both brain and cardiac.
- The top three phenotypes associated with the Sap130 CHIP-seq analysis were global brain delay, abnormal brain
- 603 development, and abnormal nervous system development.

604 Crisper/CAS Phenotype Validation

- 605 Crisper/CAS9 mice were also processed via ECM for validation of phenotype associated with Ohia mice. Three
- different crisper/CAS mice were developed to validate, a Sap130/Pcdha9 double mutant, Sap130 only and Pchda9
- only. Brain scoring was performed like Ohia mice and findings support a similar phenotype. In the Sap130/Pcdha9

double mutant mice analyzed, they were found to exhibit a severe phenotype characterized by smoothed

609 cerebellum, aplastic or highly dysplastic olfactory bulbs, and aplastic hippocampus. Other animals showed a

610 pattern of holoprosencephaly. The Sap130 crisper animal showed a severe phenotype as well with smooth

611 cerebellum, absent or extremely abnormal olfactory bulbs, and either holoprosencephaly or an abnormal

hippocampus. In the Pcdha9 crisper animal, the phenotype was milder and presented with a cerebellum that while

dysplastic did present with fissures unlike the double mutant or Sap130 crisper animal, a semi-normal appearing

olfactory bulb and hippocampus. The phenotype was more severe in animals having mutations in the Sap130 gene.

A visual representation of the defects found in Crisper/CAS9 mice can be found in Supplemental Figure 8. A

similar pattern of severe olfactory bulb and hippocampal structural abnormalities was seen in our human

population. Supplemental Figure 9 shows the Crisper/CAS animals compared to a human subject with severe brain
 dysmaturation.

620 Discussion

621 Our study validates a paralimbic related subcortical based semi-quantitative BDS, which has proven to be 622 sensitive to dysmaturational differences between CHD and control infants as well as sensitive to 623 neurodevelopmental outcomes within CHD infants, including associations with early language, clinical and feeding 624 outcomes. Most conventional semi-quantitative MRI scoring systems in CHD patients have exclusively focused on either acquired brain injury or cortical maturation assessment, particularly in the neonatal period.²⁶⁻³³ In this study, 625 626 we demonstrated that not only is it possible to generate a paralimbic-related subcortically informed scoring system, 627 but that such a scoring system holds important information regarding outcomes for CHD infants at risk for atypical 628 neurodevelopment. The key subcortical components of our scoring system included subcortical structures that are 629 known to be part of para-limbic neural networks including the olfactory bulb, the hippocampus, the cerebellum and 630 the deep grey structures like the striatum. Furthermore, we showed that there is a distinct similarity between 631 findings seen in CHD infants when compared to a preclinical mouse model of CHD suggesting similar mechanisms 632 of brain dysmaturation.

633 In our study, we found a high incidence of paralimbic related subcortical abnormalities including 634 olfactory, cerebellar, hippocampal, and brainstem abnormalities in infants with CHD compared to controls. We 635 found similar olfactory bulb defects in the preclinical mouse model that we also see in our human CHD population. 636 These abnormalities were used to derive a semi-quantitative subcortical abnormality or brain dysplasia score 637 (BDS). We found that this BDS correlated with reduced cortical maturation (measured with the classic TMS). 638 increased CSF volume and increased deep grey volume (striatum/thalamus). In contrast, the BDS did not correlate 639 with GA, preterm status, cardiac lesion subtype, birth factors, intraoperative factors, or different vendor MRI/field 640 strength. BDS did correlate with developmental delay and poor expressive language development. The BDS also 641 correlates with age at surgery, increased length of hospitalization and need for G-tube placement. A more detailed 642 evaluation of factors surrounding feeding and individual brain dysplasia parameters found correlations between 643 lack oral feeding prior to neonatal hospital discharge and dysplasia of multiple brain areas as well as the BDS, and 644 additionally with hospital length of stay which is likely the sequala of feeding dysfunction. Interestingly, 645 swallowing dysfunction was associated with dysplasia of the brain stem.

An important component of our paralimbic-related subcortical BDS scoring system is the hippocampus. 646 647 We found a consistent pattern of dysmaturation in the hippocampus, including severe forms of hippocampal aplasia 648 or dysplasia in both mice and human subjects. Research has indicated that reductions in hippocampal volume and functional correlates in adolescents and adults resulted in an increased rate of neurodevelopmental impairment ^{74,75}. 649 650 Fontes et. al found that hippocampal shape and volumetric abnormalities found within CHD subjects can be 651 predictive of impaired executive function. It is possible that the hippocampus is particularly vulnerable to early 652 injury in CHD individuals as it is a brain region particularly susceptible to injury related to hypoxemia or 653 hemodynamic instability. Latal et al found that reductions in hippocampal volume correlated with reductions in 654 total IQ, working memory, and verbal comprehension. Lastly, one study looking at maternal stress found that reductions in hippocampal volumes are present in utero, consistent with previous volumetric findings of CHD⁷⁶. 655 656 Wu et. al concluded that universal screening looking at maternal stress is important, as early identification of 657 hippocampal abnormalities is imperative.

658 Another important component of our paralimbic-related subcortical scoring system was the cerebellum. Cerebellar dysfunction has been linked with adverse neurodevelopmental outcomes⁷⁷⁻⁷⁹. Stoodley found that 659 660 cerebellar damage or malformation present in early stages of development to be more detrimental than when 661 obtained in adulthood, and theorized that injuries could affect cerebral-cerebellar circuits that are crucial to development and learning.⁷⁸ Zwicker et. al found that preterm infants with exposure to morphine in the neonatal 662 period had decreased cerebellar volumes and worse neurodevelopmental outcomes.⁷⁹ Additionally, our group has 663 previously shown that CHD children with reduced cerebellar volumes scored worse in tests for working memory, 664 inhibitory control, and mental flexibility⁸⁰. We also demonstrated that the superior surface of the cerebellum, 665 666 primarily composed of the posterior lobe and the midline vermis, is an area particularly susceptible to alterations in morphology, indicating possible regions specifically affected by dysmaturation in CHD.³⁵ Previous literature in 667 combination with our BDS findings show the importance of the cerebellum toward neurodevelopment and suggest 668 that insults or injury affecting proper cerebellar development may impact neurodevelopmental outcomes. Figure 4 669 670 demonstrates some of the commonalities seen between the mouse and human cerebellum; of note are the abnormal 671 number cerebellar fissure and small size.

672 An important subcortical structure that was noted to be abnormal in the human BDS score volumetric 673 correlation analysis and in the preclinical modeling was the striatum. In infancy, striatal connectivity is related to 674 later motor and affective outcomes⁸¹⁻⁸³, with previous research suggesting there are abnormalities in CHD⁸⁴, potentially linking disrupted development with future behavior. The striatum forms a neural network with indirect 675 676 and direct connectivity with other subcortical paralimbic components of the BDS score including the cerebellum. 677 hippocampus and olfactory bulb. As such the developing striatum is part of a dense, interconnected network that supports motor function, reward processing, and cognition 85,86 , with circuitry specialized for affective based 678 679 learning and olfactory reward. Supported by work in animal models and adults, the olfactory bulb directly projects 680 to the olfactory tubercle⁸⁷, a part of the ventral striatum, specialized for olfaction and containing significant dopamine neurons^{88,89}. Together with innervations to the striatum from the hippocampus and amygdala⁹⁰⁻⁹³, the 681 ventral striatum has been suggested to represent odor valence cues and instigate goal-directed behavior⁸⁷, facilitated 682 by additional input from piriform cortex and prefrontal cortex⁹⁴⁻⁹⁶. Output from the ventral striatum proceeds to the 683 pallidum and then the thalamus, which then closes the feedback loop with prefrontal cortex^{97,98}. An important 684 structure in this loop is the orbitofrontal cortex, which plays an important role in maintaining changing odor 685 representations but also more broadly in decision making and stimulus evaluation⁹⁹. Integrated into these loops are 686 687 other subcortical structures, including the cerebellum, which also has a significant role in movement and more 688 recently emphasized role in cognition and language¹⁰⁰. Through the thalamus and pons, the cerebellum indirectly projects to putamen, pallidum and the subthalamic nucleus^{101,102}. These outputs may be topographically organized, 689 690 converging on both the ventral striatum and frontal areas, with suggested involvement in appetitive reward¹⁰³ and 691 strategic motor learning¹⁰⁴. Disruption of this interconnected network is likely captured by BDS scores, which are then sensitive to striatally relevant neurodevelopmental outcomes. 692

693 Within the Ohia mouse model the two main driver genes were Sap130 and Pcdha9, and while both genes 694 were necessarily to have cardiac phenotype, both genes were not required to have neuroanatomic abnormalities. 695 Additionally, Sap130 mutations presented with a more severe brain phenotype compared to Pcdha9 mutations. 696 This is interesting as knock-out mice for Sap130 are embryonically lethal whereas Pcdha9 knock-out mice are viable suggesting that Sap130 may have a more upstream effect whereas Pcdha9 is more downstream.¹⁰⁵ Sap130 697 698 functions as a subunit of the histone deacetylase dependent co-repressor complex which has roles transcriptional 699 regulation and has been specifically mentioned to be required for recovery from hypoxia.¹⁰⁶ Pcdha9 is a member of 700 the protocadherin alpha gene cluster which are important plasma membrane proteins for cell-cell connections, 701 neural projects, and synapse formation.¹⁰⁷ Interestingly both genes show overlap in connectomes with chromatin and histone modification pathways.⁴⁴ Alterations in histone modifying pathways have been linked to various forms 702 of CHD. ¹⁰⁸⁻¹¹⁰ It's likely that there are many other genes and gene pairings that could cause a similar 703 704 neurodevelopmental phenotype as it's possible the main driver could be epigenetic dysregulation resulting in 705 altered differential expression of genes required for signaling and migration. Incorrect timing for migrating neural 706 cells might explain why preterm babies and CHD babies look phenotypically similar in regard to 707 neurodevelopment. Looking at the genetics of the preclinical mouse model could not be conclusive as to the 708 etiology of the human CHD neurodevelopmental issues; however, we demonstrate spectra of cardiac and brain 709 anatomical abnormalities associated with the different genetic combinations of the Ohia mouse, parallel to those 710 seen in human subjects.

711 CHD subjects have a documented risk of poor neurodevelopmental outcomes although the specific mechanism is unknown.¹¹¹⁻¹¹⁵ Additionally, neurodevelopmental impairments can continue to affect individuals 712 well past infancy and into adolescence and early adulthood.¹¹⁶⁻¹²¹ There are two main hypotheses with regard to the 713 714 origin of injury to the brain and subsequent neurodevelopmental deficits that arise from the injury; intrinsic patient 715 factors including genetics or altered substrate delivery due to the cardiac malformation. There have been studies 716 looking at the heritability of CHD to determine the genetic causes which resulted in the finding that CHD most 717 likely has a genetic component. CHD is particularly common in genetic syndromes caused by aneuploidy defects; ranging anywhere from 20% - 100% of individuals with trisomies 13, 18, and 21 as well as and monosomy X^{122} , 718 719 though these syndromic cases account for a relatively low amount of the total CHD population. Additionally, rates 720 of CHD are increased when there are abnormal chromosomal structural syndromes such as deletions, insertions, 721 and copy number variants.¹²³ Known de novo single nucleotide polymorphisms account for approximately 10% of CHD cases, roughly the same amount that can be attributed to environmental factors.^{123,124} However, the vast 722 723 majority of CHD individuals have an unknown origin of the cardiac defect as well as subsequent 724 neurodevelopmental abnormalities. To overcome this missing data, work has begun looking at previously 725 uncharacterized de novo mutations in mice, singling out genes with human homologs and which have high

expression in the heart. When looking at only the homologous genes, researchers found that between CHD and control individuals, there was no significant difference between rates of generic de novo mutations; however, when comparing genes with high cardiac expression, CHD subjects had much higher rates of mutations in proteinaltering mutations.¹²⁵ This recent work into the genetic origins of CHD has shown that even when the cause of the insult is unknown, the cause of CHD is likely genetic possibly through the alteration of genes which affect similar downstream pathways.

732 Whether the genetic insult is the main driver or whether the mutations leave the individual susceptible to 733 other forms of injury is unknown. Our group has previously looked at how the developing subcortical paralimbic-734 related structures of the brain can be linked to energy metabolism and found that subcortical morphological 735 differences were not likely linked to prematurity or white matter injury alone, but that there was a linkage between 736 brain metabolism and subcortical structural morphometry.⁵⁸ Stemming from these findings, we believe that 737 subplate vulnerability in the prenatal and immediate post-natal period can be informative to understanding the 738 subcortical dysmaturation seen in CHD infants. Within CHD individuals, it's been shown that preoperatively they 739 have volumetric abnormalities present in the cerebellum and brainstem¹⁶ and additionally that abnormal cerebellar growth has been linked with worse outcomes in expressive communication and the adaptive development quotient 740 741 in CHD individuals.¹² Furthermore, there is an established link between subcortical morphological abnormalities 742 and white matter vulnerability which can lead to injury and eventual worse neurodevelopmental outcomes.^{17,20} 743 With the mounting evidence of the importance of subcortical structures for proper brain development, and the 744 subcortical structures' relationship to proper cortical development, inclusion of subcortical structures into our 745 scoring system is necessary to characterize the entire picture of brain dysplasia. With nearly half of CHD cases still 746 without a known genetic origin, identifying subtle cases of neurodevelopmental abnormalities in CHD individuals 747 can better help us understand the downstream effects of CHD on brain development, ultimately furthering 748 knowledge of the interplay between CHD and neurodevelopmental outcomes. Importantly, early interventional 749 strategies have shown promise in helping CHD individuals with potential neurocognitive difficulties¹²⁶ and early 750 identification of the most vulnerable through proper screening is necessary to identify and target therapies toward 751 highest risk individuals.

752 Limitations

753 Our study does have some important limitations. The preterm and term CHD cohorts that we studied were 754 heterogenous related to heart lesion subtypes. During this study, only a limited number of socio-demographic 755 factors were prospectively collected and therefore analysis using these factors was unable to be carried out and 756 future work correlating BDS score with pediatric/adolescent neurocognitive outcomes in relation to socio-757 demographic factors is needed. Our multi-site approach with different scanner platforms and vendors can lead to 758 interscanner variance, but our secondary analyses did not find a correlation between scanner vendor or field 759 strength and brain dysplasia score. Future work employing retrospective machine learning techniques like the 760 empirical Bayes technique (Combat) can be used to reduce interscanner variance. Importantly, we were not able to 761 measure extra-axial CSF fluid in the ECM imaging of the mouse mutants, which is an important component of the 762 BDS score. Complete removal of CSF and infiltration of paraffin could have altered CSF volumes or the ventricle 763 shape. With this in mind, we did not feel comfortable labeling these brain regions as containing CSF and instead 764 labeled them as extra-axial space.

765

766 Contributors

- 767 Conceptualization: WTR, JVS, GG, VL,
- 768 Data Curation: WTR, JVS, GG, VL,
- 769 Manuscript Draft Preparation: WTR, JVS, GG, VL,
- 770 Manuscript Editing: WTR, JVS, GG, VL,
- 771 Statistical Analysis: VL, VS
- Human Quantitative Scoring and Reads: SS, AP
- 773 Human Volumetric Segmentation: WTR,

- Human Cardiac Lesion Characterization: JVS,
- 775 Mouse Quantitative Scoring: WTR, YW, AP
- 776 Mouse Volumetric Segmentation: RS,AP
- 777 Supervision: CL, AP
- 778 Verification of Underlying Data: WTR
- 779 **Declaration of Interests**
- 780 The authors declare that there are no conflicts of interest.
- 781 Acknowledgments

782 This work was supported by the Department of Defense (W81XWH-16-1-0613), the National Heart, Lung, and 783 Blood Institute (R01 HL152740-1, R01 HL128818-05), and the National Heart, Lung and Blood Institute with 784 National Institute on Aging (R01HL128818-05 S1). Southern California Clinical and Translational Sciences 785 Institute (NCATS) through Grant UL1TR0001855. Its contents are solely the responsibility of the authors and do 786 not necessarily represent the official views of the NIH. We also acknowledge Additional Ventures for support (AP, 787 VR, RC). VR is supported by the Saban Research Institute, Additional Ventures Foundation and NIH-NHLBI 788 K01HL153942. NT is supported by Children's Hospital Los Angeles Clinical Services Research Grant and the 789 NINR K23 Grant 1K23NR019121-01A1.

790

791 Data Sharing Statement

792 Preclinical mouse data can be made available upon request to corresponding author. Clinical data cannot be made

public due to privacy issues, but limited data can be made available upon special request to the corresponding
 author with justification for the data request.

795 References

 Hoffman JI, Kaplan S. The incidence of congenital heart disease. J Am Coll Cardiol 2002; 39(12): 1890-900.

- Sun R, Liu M, Lu L, Zheng Y, Zhang P. Congenital Heart Disease: Causes, Diagnosis, Symptoms, and
 Treatments. *Cell Biochemistry and Biophysics* 2015; **72**(3): 857-60.
- Rollins CK, Newburger JW, Roberts AE. Genetic contribution to neurodevelopmental outcomes in
 congenital heart disease: are some patients predetermined to have developmental delay? *Current Opinion in Pediatrics* 2017; 29(5): 529-33.
- 4. Jin SC, Homsy J, Zaidi S, et al. Contribution of rare inherited and de novo variants in 2,871 congenital
 heart disease probands. *Nature Genetics* 2017; **49**(11): 1593-601.
- 805 5. Homsy J, Zaidi S, Shen Y, et al. De novo mutations in congenital heart disease with neurodevelopmental 806 and other congenital anomalies. *Science* 2015; **350**(6265): 1262-6.
- 807 6. Ji W, Ferdman D, Copel J, et al. De novo damaging variants associated with congenital heart diseases 808 contribute to the connectome. *Scientific Reports* 2020; **10**(1).
- 809 7. Hayek C, Rajagopalan V, Meouchy J, et al. Ventricular and total brain volumes in infants with congenital
 810 heart disease: a longitudinal study. *Journal of Perinatology* 2020; 40(9): 1383-8.
- 811 8. Bonthrone AF, Dimitrova R, Chew A, et al. Individualized brain development and cognitive outcome in 812 infants with congenital heart disease. *Brain Commun* 2021; **3**(2): fcab046.

- 813 9. Bonthrone AF, Kelly CJ, Ng IHX, Counsell SJ. MRI studies of brain size and growth in individuals with 814 congenital heart disease. *Translational Pediatrics* 2021; **10**(8): 2171-81.
- 815 10. Stinnett GR, Lin S, Korotcov AV, et al. Microstructural Alterations and Oligodendrocyte Dysmaturation
 816 in White Matter After Cardiopulmonary Bypass in a Juvenile Porcine Model. *Journal of the American Heart*817 Association 2017; 6(8): e005997.
- Morton PD, Korotcova L, Lewis BK, et al. Abnormal neurogenesis and cortical growth in congenital heart
 disease. *Science translational medicine* 2017; 9(374): eaah7029.
- Wong A, Chavez T, O'Neil S, et al. Synchronous Aberrant Cerebellar and Opercular Development in
 Fetuses and Neonates with Congenital Heart Disease: Correlation with Early Communicative Neurodevelopmental
 Outcomes, Initial Experience. *American Journal of Perinatology Reports* 2017; 7(01): e17-e27.
- von Rhein M, Buchmann A, Hagmann C, et al. Brain volumes predict neurodevelopment in adolescents
 after surgery for congenital heart disease. *Brain : a journal of neurology* 2014; **137**(Pt 1): 268-76.
- von Rhein M, Buchmann A, Hagmann C, et al. Severe congenital heart defects are associated with global
 reduction of neonatal brain volumes. *The Journal of pediatrics* 2015; **167**(6): 1259-63. e1.
- 827 15. Owen M, Shevell M, Donofrio M, et al. Brain volume and neurobehavior in newborns with complex
 828 congenital heart defects. *J Pediatr* 2014; 164(5): 1121-7 e1.
- 829 16. Ortinau C, Beca J, Lambeth J, et al. Regional alterations in cerebral growth exist preoperatively in infants
 830 with congenital heart disease. *The Journal of Thoracic and Cardiovascular Surgery* 2012; 143: 1264-70.
- 17. Volpe JJ. Brain injury in premature infants: a complex amalgam of destructive and developmental
 disturbances. *Lancet neurology* 2009; 8(1): 110-24.
- 18. Volpe JJ. Brain injury in the premature infant: overview of clinical aspects, neuropathology, and
 pathogenesis. *Seminars in Pediatric Neurology* 1998; **5**: 135-51.
- Ligam P, Haynes RL, Folkerth RD, et al. Thalamic damage in periventricular leukomalacia: novel
 pathologic observations relevant to cognitive deficits in survivors of prematurity. *Pediatr Res* 2009; 65(5): 524-9.
- Wisnowski JL, Ceschin RC, Choi SY, et al. Reduced thalamic volume in preterm infants is associated
 with abnormal white matter metabolism independent of injury. *Neuroradiology* 2015; **57**(5): 515-25.
- Panigrahy A, Lee V, Ceschin R, et al. Brain Dysplasia Associated with Ciliary Dysfunction in Infants with
 Congenital Heart Disease. *The Journal of Pediatrics* 2016; **178**: 141-8. e1.
- 22. Ceschin R, Zahner A, Reynolds W, et al. A computational framework for the detection of subcortical brain
 dysmaturation in neonatal MRI using 3D Convolutional Neural Networks. *NeuroImage* 2018; **178**: 183-97.
- 843 23. Heye KN, Knirsch W, Latal B, et al. Reduction of brain volumes after neonatal cardiopulmonary bypass
 844 surgery in single-ventricle congenital heart disease before Fontan completion. *Pediatric research* 2018; **83**(1): 6370.
- von Rhein M, Buchmann A, Hagmann C, et al. Severe congenital heart defects are associated with global
 reduction of neonatal brain volumes. *The Journal of pediatrics* 2015; **167**(6): 1259-63. e1.
- Watson CG, Stopp C, Wypij D, Newburger JW, Rivkin MJ. Reduced cortical volume and thickness and
 their relationship to medical and operative features in post-Fontan children and adolescents. *Pediatric research*2017; **81**(6): 881-90.
- Alablani FJ, Chan HSA, Beishon L, et al. Paediatric brain MRI findings following congenital heart
 surgery: a systematic review. *Archives of disease in childhood* 2022; **107**(9): 818-25.

Bhattacharjee I, Mohamed MA, Nandakumar V, Friedman NR, Ruggieri P, Aly H. Scoring of brain
 magnetic resonance imaging and neurodevelopmental outcomes in infants with congenital heart disease. *Early human development* 2022; 169: 105574.

Brossard-Racine M, du Plessis A, Vezina G, et al. Brain injury in neonates with complex congenital heart
disease: what is the predictive value of MRI in the fetal period? *Am J Neuroradiol* 2016; **37**(7): 1338-46.

Dijkhuizen EI, de Munck S, de Jonge RCJ, et al. Early brain magnetic resonance imaging findings and
 neurodevelopmental outcome in children with congenital heart disease: A systematic review. *Developmental Medicine & Child Neurology* 2023.

30. Li Y, Yin S, Fang J, et al. Neurodevelopmental delay with critical congenital heart disease is mainly from
prenatal injury not infant cardiac surgery: current evidence based on a meta - analysis of functional magnetic
resonance imaging. *Ultrasound in Obstetrics & Gynecology* 2015; **45**(6): 639-48.

McCarthy AL, Winters ME, Busch DR, et al. Scoring system for periventricular leukomalacia in infants
 with congenital heart disease. *Pediatric research* 2015; **78**(3): 304-9.

Mulkey SB, Swearingen CJ, Melguizo MS, et al. Multi-tiered analysis of brain injury in neonates with
 congenital heart disease. *Pediatric cardiology* 2013; **34**: 1772-84.

Stegeman R, Feldmann M, Claessens NHP, et al. A uniform description of perioperative brain MRI
 findings in infants with severe congenital heart disease: results of a European collaboration. *Am J Neuroradiol* 2021; 42(11): 2034-9.

Panigrahy A, Lee V, Ceschin R, et al. Brain Dysplasia Associated with Ciliary Dysfunction in Infants with
 Congenital Heart Disease. *The Journal of pediatrics* 2016.

873 35. Ceschin R, Zahner A, Reynolds W, et al. A computational framework for the detection of subcortical brain
 874 dysmaturation in neonatal MRI using 3D Convolutional Neural Networks. *NeuroImage* 2018.

875 36. Gabriel GC, Salamacha N, Reynolds WT, et al. Characterization of Neurodevelopmental Defects

Associated With a Mouse Model of Hypoplastic Left Heart Syndrome. *Circulation* 2018; **138**(Suppl_1): A16609A.

878 37. Panigrahy A, Ceschin R, Lee V, et al. Respiratory Ciliary Motion Defect Predict Regional Brain
879 Abnormalities and Increased Extra Axial CSF Fluid in Neonates With Complex Congenital Heart Disease.
880 *Circulation* 2014; **130**(Suppl 2): A16570-A.

38. Panigrahy A, Votava-Smith J, Lee V, et al. Abnormal Brain Connectivity and Poor Neurodevelopmental
Outcome in Congenital Heart Disease Patients With Subtle Brain Dysplasia. *Circulation* 2015; 132(Suppl 3):
A16541-A.

Subramanian S, Soundara Rajan D, Gaesser J, Wen-Ya Lo C, Panigrahy A. Olfactory bulb and olfactory
 tract abnormalities in acrocallosal syndrome and Greig cephalopolysyndactyly syndrome. *Pediatric Radiology* 2019; 49(10): 1368-73.

40. Votava-Smith JK, Schmithorst VJ, Tran N, et al. Impaired Pre-Operative Cerebral Autoregulation is
Associated With Functional Brain Dysmaturation in Neonatal Congenital Heart Disease. *Circulation* 2017;
136(suppl_1): A15580-A.

Votava-Smith JK, Gaesser J, Harbison AL, et al. Clinical factors associated with microstructural
 connectome related brain dysmaturation in term neonates with congenital heart disease. *Frontiers in neuroscience* 2022; 16: 952355.

Limperopoulos C, Tworetzky W, McElhinney DB, et al. Brain volume and metabolism in fetuses with
congenital heart disease: evaluation with quantitative magnetic resonance imaging and spectroscopy. *Circulation*2010; **121**: 26-33.

Sun L, Macgowan CK, Sled JG, et al. Reduced fetal cerebral oxygen consumption is associated with
 smaller brain size in fetuses with congenital heart disease. *Circulation* 2015; **131**: 1313-23.

Liu X, Yagi H, Saeed S, et al. The complex genetics of hypoplastic left heart syndrome. *Nature genetics*2017; 49(7): 1152-9.

900 45. Thu CA, Chen WV, Rubinstein R, et al. Single-cell identity generated by combinatorial homophilic 901 interactions between α , β , and γ protocadherins. *Cell* 2014; **158**(5): 1045-59.

46. Mountoufaris G, Chen WV, Hirabayashi Y, et al. Multicluster Pcdh diversity is required for mouse
olfactory neural circuit assembly. *Science* 2017; **356**(6336): 411-4.

- 904 47. Anitha A, Thanseem I, Nakamura K, et al. Protocadherin α (PCDHA) as a novel susceptibility gene for 905 autism. Journal of Psychiatry and Neuroscience 2013; 38(3): 192-8. 906 Witteveen JS, Willemsen MH, Dombroski TC, et al. Haploinsufficiency of MeCP2-interacting 48. 907 transcriptional co-repressor SIN3A causes mild intellectual disability by affecting the development of cortical 908 integrity. Nature Genetics 2016; 48(8): 877-87. 909 49. Amir RE, Van den Veyver IB, Wan M, Tran CQ, Francke U, Zoghbi HY. Rett syndrome is caused by 910 mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nature genetics 1999; 23(2): 185-8.
- 50. Ballas N, Grunseich C, Lu DD, Speh JC, Mandel G. REST and its corepressors mediate plasticity of
 neuronal gene chromatin throughout neurogenesis. *Cell* 2005; **121**(4): 645-57.
- Gao Z, Ure K, Ding P, et al. The master negative regulator REST/NRSF controls adult neurogenesis by
 restraining the neurogenic program in quiescent stem cells. *Journal of Neuroscience* 2011; **31**(26): 9772-86.
- 52. Wisnowski JL, Schmithorst VJ, Rosser T, et al. Magnetic resonance spectroscopy markers of axons and
 astrogliosis in relation to specific features of white matter injury in preterm infants. *Neuroradiology* 2014; 56: 7719.
- 918 53. Wisnowski JL, Bluml S, Paquette L, et al. Altered Glutamatergic Metabolism Associated with Punctate
 919 White Matter Lesions in Preterm Infants. *Plos One* 2013; 8(2).
- 54. Blüml S, Wisnowski JL, Nelson MD, Paquette L, Panigrahy A. Metabolic maturation of white matter is
 altered in preterm infants. *Plos One* 2014; 9: e85829.
- Blüml S, Wisnowski JL, Nelson Jr MD, Paquette L, Panigrahy A. Metabolic maturation of white matter is
 altered in preterm infants. *Plos One* 2014; 9(1): e85829.
- Blüml S, Wisnowski JL, Nelson MD, et al. Metabolic maturation of the human brain from birth through
 adolescence: insights from in vivo magnetic resonance spectroscopy. *Cerebral Cortex* 2013; 23(12): 2944-55.
- 57. Ceschin R, Wisnowski JL, Paquette LB, Nelson MD, Blüml S, Panigrahy A. Developmental synergy
 between thalamic structure and interhemispheric connectivity in the visual system of preterm infants. *NeuroImage: Clinical* 2015.
- 58. Gertsvolf N, Votava-Smith JK, Ceschin R, et al. Association between Subcortical Morphology and
 Cerebral White Matter Energy Metabolism in Neonates with Congenital Heart Disease. *Scientific reports* 2018; 8.
- 931 59. Harbison AL, Votava-Smith JK, Del Castillo S, et al. Clinical Factors Associated with Cerebral
 932 Metabolism in Term Neonates with Congenital Heart Disease. *The Journal of Pediatrics* 2017.
- 933 60. Paquette LB, Votava-Smith JK, Ceschin R, et al. Abnormal development of thalamic microstructure in
 934 premature neonates with congenital heart disease. *Pediatric cardiology* 2015; **36**(5): 960-9.
- 61. Schmithorst VJ, Votava Smith JK, Tran N, et al. Structural network topology correlates of
 microstructural brain dysmaturation in term infants with congenital heart disease. *Human brain mapping* 2018;
 39(11): 4593-610.
- Wisnowski JL, Blüml S, Paquette L, et al. Altered glutamatergic metabolism associated with punctate
 white matter lesions in preterm infants. *Plos One* 2013; 8(2): e56880.
- Wisnowski JL, Schmithorst VJ, Rosser T, et al. Magnetic resonance spectroscopy markers of axons and
 astrogliosis in relation to specific features of white matter injury in preterm infants. *Neuroradiology* 2014: 1-9.
- 942 64. Paquette LB, Wisnowski JL, Ceschin R, et al. Abnormal cerebral microstructure in premature neonates
 943 with congenital heart disease. *AJNR American journal of neuroradiology* 2013; **34**: 2026-33.
- Panigrahy A, Ceschin R, Lee V, et al. Respiratory Ciliary Motion Defect Predict Regional Brain
 Abnormalities and Increased Extra Axial CSF Fluid in Neonates With Complex Congenital Heart Disease.
- 945 Abnormanues and increased Extra Axia CSF Fluid in Neonales with Complex Congenital Heart 946 *Circulation* 2014; **130**(suppl_2): A16570-A.

947 66. Panigrahy A, Votava-Smith J, Lee V, et al. Abnormal Brain Connectivity and Poor Neurodevelopmental 948 Outcome in Congenital Heart Disease Patients With Subtle Brain Dysplasia. Circulation 2015; 132(suppl 3): 949 A16541-A. 950 67. Votava-Smith JK, Tran N, Abbott J, et al. Impaired Cerebral Autoregulation is Associated With Brain 951 Abnormalities in Neonatal Congenital Heart Disease: Initial Experience. Circulation 2016; 134(suppl_1): A18081-952 A. 953 68. Lao Y, Wang Y, Shi J, et al. Thalamic alterations in preterm neonates and their relation to ventral striatum 954 disturbances revealed by a combined shape and pose analysis. Brain Structure and Function 2014: 1-20. 955 69. Shi J, Wang Y, Ceschin R, et al. A multivariate surface-based analysis of the putamen in premature 956 newborns: regional differences within the ventral striatum. *Plos One* 2013; **8**(7): e66736. 957 70. Serag A, Aljabar P, Ball G, et al. Construction of a consistent high-definition spatio-temporal atlas of the 958 developing brain using adaptive kernel regression. *Neuroimage* 2012; **59**(3): 2255-65. 959 Votava-Smith JK, Gaesser J, Harbison AL, et al. Clinical Factors Associated with Microstructural 71. 960 Connectome Related Brain Dysmaturation in Term Neonates with Congenital Heart Disease. Cold Spring Harbor 961 Laboratory; 2022. 962 72. Li Y, Klena NT, Gabriel GC, et al. Global genetic analysis in mice unveils central role for cilia in 963 congenital heart disease. Nature 2015; 521(7553): 520-4. 964 73. Damerla RR, Cui C, Gabriel GC, et al. Novel Jbts17 mutant mouse model of Joubert syndrome with cilia 965 transition zone defects and cerebellar and other ciliopathy related anomalies. Hum Mol Genet 2015; 24(14): 3994-966 4005. 967 74. Latal B, Patel P, Liamlahi R, Knirsch W, Tuura ROG, von Rhein M. Hippocampal volume reduction is 968 associated with intellectual functions in adolescents with congenital heart disease. Pediatric research 2016; 80(4): 969 531. 970 75. Fontes K, Rohlicek CV, Saint - Martin C, et al. Hippocampal alterations and functional correlates in 971 adolescents and young adults with congenital heart disease. *Human brain mapping* 2019. 972 76. Wu Y, Kapse K, Jacobs M, et al. Association of maternal psychological distress with in utero brain 973 development in fetuses with congenital heart disease. JAMA pediatrics 2020; 174(3): e195316-e. 974 77. BOLDUC ME, Limperopoulos C. Neurodevelopmental outcomes in children with cerebellar 975 malformations: a systematic review. Developmental Medicine & Child Neurology 2009; 51(4): 256-67. 976 78. Stoodley CJ. The cerebellum and neurodevelopmental disorders. The Cerebellum 2016; 15(1): 34-7. 977 79. Zwicker JG, Miller SP, Grunau RE, et al. Smaller cerebellar growth and poorer neurodevelopmental 978 outcomes in very preterm infants exposed to neonatal morphine. The Journal of pediatrics 2016; 172: 81-7. e2. 979 80. Badaly D, Beers SR, Ceschin R, et al. Cerebellar and Prefrontal Structures Associated with Executive 980 Functioning in Pediatric Patients with Congenital Heart Defects. medRxiv 2021. 981 81. Ramphal B, Whalen DJ, Kenley JK, et al. Brain connectivity and socioeconomic status at birth and 982 externalizing symptoms at age 2 years. Developmental cognitive neuroscience 2020; 45: 100811. 983 Graham AM, Buss C, Rasmussen JM, et al. Implications of newborn amygdala connectivity for fear and 82. 984 cognitive development at 6-months-of-age. Developmental cognitive neuroscience 2016; 18: 12-25. 985 83. Taoudi-Benchekroun Y, Christiaens D, Grigorescu I, et al. Predicting age and clinical risk from the 986 neonatal connectome. NeuroImage 2022; 257: 119319. 987 84. Bhroin MN, Seada SA, Bonthrone AF, et al. Reduced structural connectivity in cortico-striatal-thalamic 988 network in neonates with congenital heart disease. NeuroImage: Clinical 2020; 28: 102423. 989 85. Haber SN. Corticostriatal circuitry. Dialogues in clinical neuroscience 2022. 990 Gordon EM, Laumann TO, Marek S, et al. Individualized functional subnetworks connect human striatum 86. 991 and frontal cortex. Cerebral Cortex 2022; 32(13): 2868-84.

Giessel AJ, Datta SR. Olfactory maps, circuits and computations. *Current opinion in neurobiology* 2014;

992

87.

993 **24**: 120-32. 994 88. Millhouse OE, Heimer L. Cell configurations in the olfactory tubercle of the rat. Journal of Comparative 995 Neurology 1984; 228(4): 571-97. 89. 996 Murata K, Kanno M, Ieki N, Mori K, Yamaguchi M. Mapping of learned odor-induced motivated 997 behaviors in the mouse olfactory tubercle. Journal of Neuroscience 2015; 35(29): 10581-99. 998 90. Fudge JL, Kunishio K, Walsh P, Richard C, Haber SN. Amygdaloid projections to ventromedial striatal 999 subterritories in the primate. Neuroscience 2002; 110(2): 257-75. 1000 91. Russchen FT, Bakst I, Amaral DG, Price JL. The amygdalostriatal projections in the monkey. An 1001 anterograde tracing study. Brain research 1985; 329(1-2): 241-57. 1002 92. Kelley AE, Domesick VB, Nauta WJH. The amygdalostriatal projection in the rat—an anatomical study 1003 by anterograde and retrograde tracing methods. *Neuroscience* 1982; 7(3): 615-30. 1004 93. Krettek J, Price J. Amygdaloid projections to subcortical structures within the basal forebrain and 1005 brainstem in the rat and cat. Journal of Comparative Neurology 1978; 178(2): 225-53. 1006 94. Scott JW, McBride RL, Schneider SP. The organization of projections from the olfactory bulb to the 1007 piriform cortex and olfactory tubercle in the rat. Journal of Comparative Neurology 1980; 194(3): 519-34. 1008 95. Kosel KC, Van Hoesen GW, West JR. Olfactory bulb projections to the parahippocampal area of the rat. 1009 Journal of Comparative Neurology 1981; 198(3): 467-82. 1010 96. Zhang Z, Zhang H, Wen P, et al. Whole-brain mapping of the inputs and outputs of the medial part of the 1011 olfactory tubercle. Frontiers in Neural Circuits 2017; 11: 52. 1012 97. Leisman G, Braun-Benjamin O, Melillo R. Cognitive-motor interactions of the basal ganglia in 1013 development. Frontiers in systems neuroscience 2014; 8: 16. 1014 98. Ikemoto S. Dopamine reward circuitry: two projection systems from the ventral midbrain to the nucleus 1015 accumbens–olfactory tubercle complex. Brain research reviews 2007; 56(1): 27-78. 99. 1016 Seubert J, Freiherr J, Frasnelli J, Hummel T, Lundström JN. Orbitofrontal cortex and olfactory bulb 1017 volume predict distinct aspects of olfactory performance in healthy subjects. Cerebral Cortex 2013; 23(10): 2448-1018 56. 1019 100. De Smet HJ, Paquier P, Verhoeven J, Mariën P. The cerebellum: its role in language and related cognitive 1020 and affective functions. Brain and language 2013; 127(3): 334-42. 1021 101. Hoshi E, Tremblay L, Féger J, Carras PL, Strick PL. The cerebellum communicates with the basal ganglia. 1022 *Nature neuroscience* 2005; **8**(11): 1491-3. 1023 Bostan AC, Dum RP, Strick PL. The basal ganglia communicate with the cerebellum. *Proceedings of the* 102. 1024 national academy of sciences 2010; 107(18): 8452-6. 1025 103. O'Doherty JP, Dayan P, Friston K, Critchley H, Dolan RJ. Temporal difference models and reward-related 1026 learning in the human brain. Neuron 2003; 38(2): 329-37. 1027 104. Hikosaka O, Nakamura K, Sakai K, Nakahara H. Central mechanisms of motor skill learning. Current 1028 opinion in neurobiology 2002; 12(2): 217-22. 1029 Yagi H, Liu X, Gabriel GC, et al. The Genetic Landscape of Hypoplastic Left Heart Syndrome. Pediatr 105. 1030 Cardiol 2018; 39(6): 1069-81. 1031 Tiana M, Acosta-Iborra B, Puente-Santamaria L, et al. The SIN3A histone deacetylase complex is 106. 1032 required for a complete transcriptional response to hypoxia. Nucleic Acids Res 2018; 46(1): 120-33. 1033 Asahina H, Masuba A, Hirano S, Yuri K. Distribution of protocadherin 9 protein in the developing mouse 107. 1034 nervous system. Neuroscience 2012; 225: 88-104.

- 1035 108. Wu Y, Jin X, Zhang Y, Zheng J, Yang R. Genetic and epigenetic mechanisms in the development of 1036 congenital heart diseases. *World J Pediatr Surg* 2021; **4**(2): e000196.
- 1037 109. Bruneau BG. Signaling and transcriptional networks in heart development and regeneration. *Cold Spring* 1038 *Harb Perspect Biol* 2013; 5(3): a008292.
- 1039 110. Zhang QJ, Liu ZP. Histone methylations in heart development, congenital and adult heart diseases.
 1040 *Epigenomics* 2015; 7(2): 321-30.
- 1041 111. Marino BS, Lipkin PH, Newburger JW, et al. Neurodevelopmental outcomes in children with congenital
 1042 heart disease: evaluation and management: a scientific statement from the American Heart Association. *Circulation* 1043 2012; 126(9): 1143-72.
- 1044 112. Newburger JW, Sleeper LA, Bellinger DC, et al. Early Developmental Outcome in Children With 1045 Hypoplastic Left Heart Syndrome and Related Anomalies. *Circulation* 2012; **125**(17): 2081-91.
- 1046 113. Sananes R, Manlhiot C, Kelly E, et al. Neurodevelopmental outcomes after open heart operations before 3
 1047 months of age. *Ann Thorac Surg* 2012; 93(5): 1577-83.
- 1048 114. von Rhein M, Dimitropoulos A, Valsangiacomo Buechel ER, Landolt MA, Latal B. Risk factors for
 1049 neurodevelopmental impairments in school-age children after cardiac surgery with full-flow cardiopulmonary
 1050 bypass. J Thorac Cardiovasc Surg 2012; 144(3): 577-83.
- 1051 115. Naef N, Liamlahi R, Beck I, et al. Neurodevelopmental Profiles of Children with Congenital Heart
 1052 Disease at School Age. *J Pediatr* 2017; **188**: 75-81.
- 1053 116. Verrall CE, Blue GM, Loughran-Fowlds A, et al. 'Big issues' in neurodevelopment for children and adults
 1054 with congenital heart disease. *Open Heart* 2019; 6(2): e000998.
- 1055 117. Sood E, Jacobs JP, Marino BS. Optimising neurodevelopmental and psychosocial outcomes for survivors
 1056 with CHD: a research agenda for the next decade. *Cardiol Young* 2021; **31**(6): 873-5.
- 1057 118. Jacobsen RM. Outcomes in Adult Congenital Heart Disease: Neurocognitive Issues and Transition of
 1058 Care. *Pediatr Clin North Am* 2020; 67(5): 963-71.
- 1059 119. Marelli A, Miller SP, Marino BS, Jefferson AL, Newburger JW. Brain in Congenital Heart Disease Across
 1060 the Lifespan: The Cumulative Burden of Injury. *Circulation* 2016; **133**(20): 1951-62.
- 1061 120. Bellinger DC, Wypij D, Rivkin MJ, et al. Adolescents with d-transposition of the great arteries corrected
 with the arterial switch procedure: neuropsychological assessment and structural brain imaging. *Circulation* 2011;
 1063 124(12): 1361-9.
- 1064 121. Schaefer C, von Rhein M, Knirsch W, et al. Neurodevelopmental outcome, psychological adjustment, and 1065 quality of life in adolescents with congenital heart disease. *Dev Med Child Neurol* 2013; **55**(12): 1143-9.
- 1066 122. Fahed AC, Gelb BD, Seidman JG, Seidman CE. Genetics of Congenital Heart Disease. *Circulation* 1067 *Research* 2013; **112**(4): 707-20.
- 1068 123. Zaidi S, Brueckner M. Genetics and Genomics of Congenital Heart Disease. *Circulation Research* 2017;
 1069 120(6): 923-40.
- 1070 124. Jenkins KJ, Correa A, Feinstein JA, et al. Noninherited Risk Factors and Congenital Cardiovascular
 1071 Defects: Current Knowledge. *Circulation* 2007; **115**(23): 2995-3014.
- 1072 125. Zaidi S, Choi M, Wakimoto H, et al. De novo mutations in histone-modifying genes in congenital heart
 1073 disease. *Nature* 2013; **498**(7453): 220-3.
- 1074 126. Cassidy AR, Butler SC, Briend J, et al. Neurodevelopmental and psychosocial interventions for
- individuals with CHD: a research agenda and recommendations from the Cardiac Neurodevelopmental Outcome
 Collaborative. *Cardiol Young* 2021; **31**(6): 888-99.
- 1077

1080 Figure and Figure Legends



Figure 1. Recruitment Flowchart and Subject Numbers. Study initially consisted of 534 subjects which were
 scored using the brain dysplasia score (BDS). Initial subjects consisted of 307 term and 116 pre-term individuals.



1086

1087 Figure 2. Hippocampal Abnormalities Were Similar Among Human and Mouse. Panel (a)(b)(c)and (d)

demonstrate abnormal hypoplastic and/or malrotated hippocampi in infants with CHD which comparable
 abnormalities noted in the mouse mutant (e). A mouse control is shown for comparison in (f) depicts an abnormal.
 Panel (b)



1092

Figure 3. Consistent Olfactory Bulb Phenotype is Visible Among Human and Mouse. (a) Human control
 subject exhibits normal olfactory bulb size and structure. (b) Mouse control showing olfactory bulb with normal
 shape and size. (c) HLHS human subject with aplastic olfactory bulbs. (d) Mouse with Congenital heart disease
 with hypoplastic olfactory bulb.



1099

Figure 4. Cerebellar Abnormalities Seen in Both Human and Mouse. Panels (a) and (b) depict a human subject
 with HLHS compared to a healthy control. The cerebellum of the HLHS subject is hypoplastic shows
 dysmaturation. Panels (c) and (d) show a mouse with HLHS and a normal control. The cerebellum of the HLHS

1103 mutant displayed hypoplasia and a lesser number of cerebellar fissures. (e) Average number of cerebellar fissures 1104 among mouse groupings. (f) Human neonatal cerebellar residual volumes with gestational age regressed out.





1107 Figure 5. Phenotype Mouse Screen Recovered Mutant Mice with Defects in Cardiac, Brain and Craniofacial.

1108 (a) From the original phenotype screen 390 mutant lines were identified. Of those 390 lines 249 had CHD and of

1109 those, 174 and 62 had craniofacial and severe brain anomalies, respectively. Of the 40 lines that didn't have CHD,

1110 33 had craniofacial and 7 had severe brain anomalies. (b) Three major groupings, congenital heart disease,

1111 craniofacial anomalies, and server brain anomalies, identified from the original phenotype screen and their

relationship to one another. The highest overlap between two conditions is congenital heart disease and craniofacial

anomalies at approximately 29% of the original 390 mutants identified.



1115

1116 **Figure 6. Mouse RNA Sequencing Analysis Shows Significant Difference in Gene Expression**. (a) Genes

1117 associated with learning and memory showed lesser expression in control mice compared to Ohia mutant mice. (b)

1118 Genes associated with feeding behavior showed an abnormal pattern in Ohia mice. Ohia mice showed a pattern of

1119 expression that was opposite compared control mice at both time points. (c) Genes associated with neuronal

- 1120 differentiation showed a opposite pattern of expression in Ohia mutant mice compared to controls. (d) Genes
- associated with synaptic transmission had a different expression pattern in Ohia mutant mice compared to controls.

Total Brain Dysplasia Score



1124

Supplemental Figure 1. Components of Human Brain Dysplasia Scoring Criteria. Our brain dysplasia scoring criteria consisted of 13 distinct observations. Supratentorial extra-axial fluid was assessed for normality, cerebellar hemisphere and vermis were assessed for hypoplasia and dysplasia, right and left olfactory bulb and olfactory

sulcus were examined for any abnormalities. Additionally, the hippocampus, corpus collosum, choroid plexus, and

1129 brainstem were checked for abnormalities.

Composite Brain Injury Score



1131

Supplemental Figure 2. Components of Composite Brain Injury Score. Brain injury score was composed of four measures: hemorrhage, infarct, hypoxic ischemia, and perinatal white matter injury. Brain injury score was

binary, if any injury was present in the above measures, the subject was considered to have a brain injury.



3D Volumetric Space: 🔲 Native Subject Space 📋 Individual Albert Space 📋 Template Space

1136

1137 Supplemental Figure 3. Flow Diagram for NeBSS, a Semi-automated Neonatal Segmentation Pipeline.

Briefly, subject MR images are input into NeBSS which has two branches. Branch A uses the Albert Neonatal
Atlas and outputs 50 distinct volumetric brain structures in the subject space. Branch B uses the Serag Neonatal

1140 Brain Atlas probability maps to output 10 volumetric brain regions.



1142

1143 Supplemental Figure 4. Flow Diagram of Sample Preparation, ECM Analysis, and Volumetric Analysis.

1144 Samples selected for analysis were first necropsied. Post-necropsy samples were dehydrated using a Sakura Tissue

1145 Tek system and processed on the ECM machine. Samples were then manually segmented using ITK-Snap before

1146 volumetric results were analyzed.



1148

1149 Supplemental Figure 5. Necropsy Among Mutant Mice Showed Variety and Differing Degree of Severity of

1150 Malformations. Mice in the mouse screen presented with craniofacial anomalies with varying degrees of severity.

1151 More mild forms of errant craniofacial anatomy presented with mild defects in the ears and eyes. Moderate forms

presented as more severe ear and eye defects as well as a shortened snout. Lastly, severe defects presented with large structural defects in the craniofacial anatomy, often with underlying structural brain defects as well.



1155

1156 Supplemental Figure 6. Individual Structures Showed a Range of Abnormality in Screen Mice. Episcopic

1157 Fluorescence Image Capture (ECM) was carried out on prepared mouse brains. Samples presented with varying

1158 degrees of abnormalities. Three major structures analyzed were olfactory bulbs, cerebellum, and hippocampus.

1159 Within each structure, mice had a variety of defects including aplasia, hypoplasia, and dysplasia.



1161

- 1162 Supplemental Figure 7. Varying Degree of Cerebral Abnormalities Present in Screen Mice. ECM analysis
- found that mice had varying degrees of severity of cerebral abnormalities including holoprosencephaly and cerebralhypoplasia.



1166

- 1167 Supplemental Figure 8. Crispr/Cas Figure Mutant Animals Showed Similar Phenotype to Screen Mice.
- 1168 Using ECM, Crispr/Cas9 mutants were analyzed and show similar phenotypes seen in mutant mice recovered from
- the phenotype screen. A similar pattern of dysplasia and aplasia were seen in the cerebellum, olfactory bulb and
- 1170 hippocampus of mice recovered in the screen.



1173

1174 Supplemental Figure 9. Holoprosencephaly and Hippocampal Malformations Seen in Human and Mouse. A,

1175 Alobar holoprosencephaly seen in Sap130 CRISPR/Cas9 deletion mouse. B, Lobar holoprosencephaly seen in

Sap130/Pcdha9 double CRISPR/Cas9 deletion mouse. C, Pcdha9 CRISPR/Cas9 deletion mouse displaying cerebral
 hypoplasia and dysmaturation as well as hippocampal abnormalities. D, Control mouse showing normal cortical

and hippocampal anatomy. E, Sap130/Pcdha9 double mutant mouse exhibiting cortical, corpus collosum, and

hippocampal abnormalities. F, Lobar holoprosencephaly and hippocampal malformations observed in human

1180 subjects with HLHS.

BDS Abnormalities (Dichotomous)	Preterm CHD	Preterm Non-	Comparison	Term CHD	Term Control	Comparison
	(<i>n</i> = 69)	CHD $(n = 51)$		(<i>n</i> = 263)	(<i>n</i> = 93)	
	Number of Subj	ects with	p-value	Number of Su	Number of Subjects with	
	Abnormality (%))		Abnormality (<i>?%</i>)	
Bilateral Cerebellar Hemispheric Hypoplasia	13 (18.84%)	1 (1.96%)	0.0049	30 (11.41%)	0 (0.00%)	0.0006
Bilateral Cerebellar Hemispheric Dysplasia	7 (10.14%)	1 (1.96%)	0.0607	15 (5.70%)	0 (0.00%)	0.0133
Cerebellar Vermis Hypoplasia	18 (26.09%)	3 (5.88%)	0.0040	58 (22.05%)	0 (0.00%)	<0.0001
Cerebellar Vermis Dysplasia	9 (13.04%)	0 (0.00%)	0.0049	23 (8.75%)	0 (0.00%)	0.0019
Dichotomized Cerebellar Composite	26 (37.68%)	3 (5.88%)	<0.0001	75 (28.52%)	0 (0.00%)	<0.0001
Right Olfactory Bulb	24 (34.78%)	4 (7.84%)	<0.0001	127 (48.29%)	8 (8.60%)	<0.0001
Left Olfactory Bulb	25 (36.23%)	4 (7.84%)	<0.0001	126 (47.91%)	9 (9.68%)	<0.0001
Right Olfactory Sulcus	23 (33.33%)	1 (1.96%)	<0.0001	109 (41.44%)	3 (3.23%)	<0.0001
Left Olfactory Sulcus	23 (33.33%)	1 (1.96%)	<0.0001	109 (41.44%)	2 (2.15%)	<0.0001
Dichotomized Olfactory Composite	28 (40.58%)	4 (7.84%)	<0.0001	127 (48.29%)	9 (9.68%)	<0.0001
Hippocampus	34 (49.28%)	11 (21.57%)	0.0019	117 (44.49%)	3 (3.23%)	<0.0001
Corpus Callosum	10 (14.49%)	0 (0.00%)	0.0045	26 (9.89%)	0 (0.00%)	0.0016
Choroid Plexus	30 (43.48%)	3 (5.88%)	<0.0001	108 (41.06%)	8 (8.60%)	<0.0001
Brainstem	10 (14.49%)	0 (0.00%)	0.0045	25 (9.51%)	0 (0.00%)	0.0020
BDS Abnormalities (Categorical)	Mean (Standard	Error)	p-value	Mean (Standar	rd Error)	p-value
Supratentorial Extra-Axial Fluid*	0.9839 (0.0989)	0.6000 (0.1069)	0.0075	0.8071	0.3516 (0.0527)	<0.0001
				(0.0495)		
Cerebellar Composite	0.6812 (0.1121)	0.0980 (0.0578)	<0.0001	0.4791	0.0000 (0.0000)	<0.0001
				(0.0536)		
Olfactory Composite	1.6912 (0.2693)	0.1961 (0.1011)	<0.0001	2.0229	0.2418 (0.0817)	<0.0001
				(0.1452)		
Subcortical BDS Composite	4.3188 (0.4043)	1.1569 (0.2046)	<0.0001	4.1141	0.6989 (0.1268)	<0.0001
				(0.2210)		

Table 1: Incidence of Subcortical Brain Dysmaturation in Preterm/Term CHD And Controls

Table 2A: Correlation of Brai	n Dysplasia Score (BDS)) with Demographic Factors	(Entire cohort: Univariate Analysis)
-------------------------------	-------------------------	----------------------------	--------------------------------------

Dependent	Independent	N-used	R-Square	p-value	estimate
BDS	Sex	490	0.000026	0.9096	-0.0359
BDS	GA	487	0.003619	0.1851	0.058461
BDS	PCA	489	0.001664	0.368	0.011933

Table 2B: Correlation of Brain Dysplasia Score (BDS) with Demographic Factors (CHD cohort, Univariate Analysis)

Dependent	Independent	N-used	R-Square	p-value	estimate
BDS	Sex	344	0.008447	0.0887	0.680037
BDS	Genetic Abnormality	252	0.045926	0.0006	-1.66277
BDS	GA	341	0.00002	0.9352	-0.00562
BDS	PCA	343	0.002649	0.3419	0.017322
BDS	Birth Weight	248	0.000337	0.7737	-9.1E-05
BDS	Pre/Post operative status	343	0.000662	0.6349	-0.18132
BDS	Term/Preterm	343	0.000651	0.6378	-0.23214

Table 2C: Correlation of Brain Dysplasia Score (BDS) with Demographic Factors in (CHD cohort, Multivariate Analysis)

			Independe	ent	Term/Pre	term	Pre/Post	
Dependent	N-used	R-Square	p-value	estimate	p-value	estimate	p-value	estimate
Sex	343	0.009957	0.0854	0.6942	0.7409	-0.1633	0.5872	-0.2074
Genetic Abnormality	252	0.048769	0.0006	-1.6806	0.3971	-0.4741	0.8911	-0.0617
GA	341	0.002196	0.6323	0.059	0.5401	-0.5386	0.5487	-0.2303
РСА	343	0.003471	0.3867	0.0168	0.6152	-0.2489	0.8939	-0.0543
Birth Weight	248	0.027317	0.4891	0.0002	0.0368	-1.4958	0.0878	-0.7169

		J~ F		Main Ind	lependent	PCA	
				_			
				Factor			
	N-	model p	R-	p-value	estimate	p-	estimate
	used		Square			value	
Hemorrhage	340	0.9876	0.000001	0.9876	0.010146		
Infarction	341	0.604	0.000794	0.604	0.345161		
Hypoxic ischemic injurv	328	0.6111	0.000794	0.6111	-0.55119	—	—
Punctate white matter lesion	342	0.8922	0.000054	0.8922	0.071424	—	
Any brain	344	0.5548	0.001021	0.5548	0.243539		
injury, dichotomized							
Brain injury composite score	344	0.9042	0.000042	0.9042	-0.03758		
Maturation, Cortical Fold	332	0.0016	0.029645	0.0016	-0.7302		
Maturation, Frontal Cortex	332	<0.0001	0.061511	< 0.0001	-0.80238	—	—
Maturation, Insular Cortex	332	<0.0001	0.067464	< 0.0001	-1.01932		
Maturation, Cortical Fold & PCA	331	0.0044	0.032554	0.001	-0.78513	0.3255	0.02414
Maturation, Frontal Cortex & PCA	331	<0.0001	0.067676	< 0.0001	-0.86858	0.1531	0.034607
Maturation, Insular Cortex & PCA	331	<0.0001	0.07442	< 0.0001	-1.10484	0.146	0.035021

Table 3: Correlation of Brain Dysplasia Score, Brain Injury and Cortical Maturation Score (TMS)

	8
Correlation with	Comparison between
BDS (term CHD	term CHD and term
and term control	control cohorts
cohort combined)	
p-value	p-value (direction)
(correlation)	
0.0749 (N.S.)	0.1476 (N.S.)
0.1329 (N.S.)	0.3784 (N.S.)
0.0535 (N.S.)	0.1476 (N.S.)
0.0433 (-)	0.1887 (N.S.)
0.0299 (-)	0.0087 (CHD > CON)
0.0517 (N.S.)	0.0026 (CHD > CON)
0.2259 (N.S.)	0.9300 (N.S.)
<0.0001 (+)	0.7398 (N.S.)
0.0008 (+)	0.3535 (N.S.)
0.0138 (-)	0.4877 (N.S.)
0.4550 (N.S.)	0.6066 (N.S.)
0.1687 (N.S.)	0.0016 (CHD > CON)
0.0391 (-)	0.1311 (N.S.)
	Correlation with BDS (term CHD and term control cohort combined) p-value (correlation) 0.0749 (N.S.) 0.1329 (N.S.) 0.0535 (N.S.) 0.0433 (-) 0.0517 (N.S.) 0.2259 (N.S.) <0.0001 (+) 0.0008 (+) 0.4550 (N.S.) 0.1687 (N.S.) 0.0391 (-)

Table 4: Association Between Brain Dysplasia Score and Term Infant Regional Brain Volumes by CHD Status

Table 5: Correlation between Brain Dysplasia Score and Clinical Feeding Outcomes

BDS Abnormalities	Lack of PO Feeds	Length of
(Clinical Outcome Correlates)	Prior to	Hospitalization
	Discharge p-value	p-value
Hippocampus	0.0025	0.0090
Right / Left Olfactory Bulbs	0.0090 / 0.0050	0.0400 / 0.0300
Right / Left Olfactory Sulci	0.0070 / 0.0070	0.0700 / 0.0700
Extra-Axial Fluid	0.0030	<0.0001
Bilateral Cerebellar Hemispheres	0.0037	<0.0001
Cerebellar Vermis	0.0001	0.0002
Brainstem	<0.0001	N.S.
Corpus Callosum	0.0010	0.0100
Choroid Plexus	0.0100	0.0020
Total Composite	0.0001	0.0020

Table 6 : Correlation	on between Brain	Dysplasia S	Score and 15-18	8 Month Neuro	developmental (Outcomes
Table 0 . Correlation	m between brum	Dyspiasia	beore and 15 1	o monun ricuro	ue velopinentai v	Jucomes

Neurodevelopmental Outcomes (n=90)	Non-Parametric			Parametric
(Total BDS Correlates)	Wilcoxon Mann-Whitney Wilcoxon Mann-Whitney Kruskal		Kruskal-	T-Test
	p-value (normal approx.)	p-value (T approx.)	Wallis	p-value
			p-value (χ2)	
Expressive Language Below Mean	0.0160	0.0190	0.0160	0.0047
Language Composite Below Mean	0.2810	0.2840	0.2790	0.2837
Language Delay	0.0380	0.0420	0.0370	0.0181
Developmental Delay (delayed in ≥ 1 domains)	0.0280	0.0303	0.0272	0.0284
Global Developmental Delay (delayed in ≥ 2 domains)	0.1070	0.1110	0.1060	0.1005

Structure	Ohia Average	Wild Type Average	P value †
BDS Total	4.42	0	<0.001
Cerebellar Fissures	1.5	4.4	<0.001
	Ohia Incidence	Wild Type Incidence	P value *
BDS Dichotomized	55/69, (79.71%)	0/10, (0.00%)	<0.001
BDS Hippocampus or Cerebellum	58/69, (84.06%)	0/10, (0.00%)	<0.001
Aplastic Hippocampus	8/69, (11.59%)	0/10, (0.00%)	0.384
Hypoplastic Hippocampus	14/68, (20.59%)	0/10, (0.00%)	0.223
Dysplastic Hippocampus	44/68, (64.71%)	0/10, (0.00%)	0.002
Combination Hippocampus	22/69, (31.88%)	0/10, (0.00%)	0.133
Hypoplastic Cerebrum	13/68, (19.12%)	0/10, (0.00%)	0.244
Dysplastic Cerebrum	43/68, (63.24%)	0/10, (0.00%)	0.003
Aplastic Cerebellum	2/69, (02.90%)	0/10, (0.00%)	0.678
Hypoplastic Cerebellum	9/67, (13.43%)	0/10, (0.00%)	0.345
Dysplastic Cerebellum	49/67, (73.13%)	0/10, (0.00%)	<0.001
Combination Cerebellum	11/69, (15.94%)	0/10, (0.00%)	0.325
Aplastic Left Olfactory Bulb	33/69, (47.83%)	0/10, (0.00%)	0.024
Aplastic Right Olfactory Bulb	34/69, (49.28%)	0/10, (0.00%)	0.02
Hypoplastic Left Olfactory Bulb	9/67, (13.43%)	0/10, (0.00%)	0.345
Hypoplastic Right Olfactory Bulb	7/65, (10.77%)	0/10, (0.00%)	0.404
Dysplastic Left Olfactory Bulb	2/67, (2.99%)	0/10, (0.00%)	0.673
Dysplastic Right Olfactory Bulb	0/65, (00.00%)	0/10, (0.00%)	—
Combination Left Olfactory Bulb	42/69, (60.87%)	0/10, (0.00%)	0.006
Combination Right Olfactory Bulb	41/69, (59.42%)	0/10, (0.00%)	0.007
Hypoplastic Brainstem	0/66, (00.00%)	0/10, (0.00%)	—
Dysplastic Brainstem	20/67, (29.85%)	0/10, (0.00%)	0.12
Hypoplastic Midbrain	0/67, (00.00%)	0/10, (0.00%)	_
Dysplastic Midbrain	18/67, (26.87%)	0/10, (0.00%)	0.148

Table 7: Incidence of Brain Dysplasia Score and Subcomponents between Ohia and Wild type Mouse Mutants

† Student's T-test was used to compare Cerebellar Fissure count and BDS Total Score.* Chi-square analysis was used to compare individual structures as well as BDS Dichotomized and BDS Hippocampus or Cerebellum.

	CHD vs. No CHD			Single vs. Biventricular Morphology		Conotruncal vs. Non Conotruncal			Cyanotic vs. Acyanotic			Arch Obstruction vs. No Obstruction			
	CHD	No CHD	P value *	Single	Double	P value *	Conotruncal	Non Conotruncal	P value *	Cyanotic	Acyanotic	P value *	Obstruction	No Obstruction	P value *
Cerebellar Fissures	1.17 ± 1.55	3.14 ± 1.67	<0.001	1.50 ± 2.12	1.16 ± 1.55	0.86	1.13 ± 1.92	1.22 ± 1.36	0.88	1.16 ± 1.80	1.19 ± 1.39	0.96	0.81 ± 0.98	1.48 ± 1.87	0.13
BDS Total	5.43 ± 2.22	2.73 ± 2.46	<0.001	7.00 ± 2.00	5.32 ± 2.20	0.21	5.27 ± 2.12	5.33 ± 2.46	0.93	5.63 ± 2.34	5.29 ± 2.17	0.61	5.87 ± 1.69	5.00 ± 2.60	0.1

Table 8: Relationship between Brain Dysplasia Scores/Cerebellar Fissures and Cardiac Lesion Subtypes in Ohia CHD/HLHS Preclinical Groups

* Student T-test used to calculate difference between population values within cerebellar fissures and Total Brain Dysmaturation Score (BDS).

Group	\mathbf{A}^{\dagger}	B‡	C§	\mathbf{D}^{\parallel}	\mathbf{E}^{\P}	$\mathbf{F}^{\#}$
N Total	24	8	7	4	0	20
Olfactory bulb abnormality	18 (75%)	6 (75%)	6 (85.7%)	4 (100%)	0	9 (45%)
Cerebellar abnormality	21 (87.5%)	7 (87.5%)	7 (100%)	4 (100%)	0	13 (65%)
Hippocampus abnormality	21 (87.5%)	7 (87.5%)	6 (85.7%)	4 (100%)	0	13 (65%)
Brainstem abnormality	10 (42%)	2 (25%)	0 (0%)	2 (50%)	0	6 (30%)

Table 9: Relationship of Genotype to Incidence of Subcortical Abnormalities used to Derive BDS score in CHD/HLHS Preclinical Groups

[†]Group A: N 24, Genotype: Pcdha9(m/m) Sap130(m/m)

‡ Group B: N 8, Genotype: Pcdha9(m/+) Sap130(m/m)

§ Group C: N 7, Genotype: Pcdha9(+/+) Sap130(m/m)

|| Group D: N 4, Genotype: Pcdha9(m/m) Sap130(m/+)

¶ Group E: N 0, Genotype: Pcdha9(m/m) Sap130(+/+)

Group F: N 27, Genotype: Pcdha9(m/+) or (+/+) Sap130(m/+) or (+/+)

P value *	://doi.org d by pee i
0.40	/10.1101/2 review) is It is made
0.558	01/2024.04.21.24306144; this version posted April 22, 2024. The copyright I w) is the author/funder, who has granted medRxiv a license to display the p nade available under a CC-BY-ND 4.0 International license .
	older for t eprint in p
	his preprint erpetuity.

Table 10: Relationship of Genotype to BDS Score in CHD/HLHS Preclinical Groups

P value*

<0.001

< 0.001

* Non-parametric Mann-Whitney U test used to analyze differences in continuous Brain Dysmaturation Score.

ABC

Median

ABC** vs. F[#]

1

6

F

Median

1

5.5

Р

value *

0.008

0.227

AB^{††} vs. F[#]

1

6

Median

F

Median

1

5.5

Р

value *

0.021

0.251

AB

 \mathbf{A}^{\dagger} vs. $\mathbf{C}^{\$}$

Median

1

6

С

Median

1

5

Р

value *

0.583

0.56

А

 \mathbf{B}^{\ddagger} vs. \mathbf{D}^{\parallel}

Median

1

6

D

Median

1

6.5

В

[†]Group A: N 24, Genotype: Pcdha9(m/m) Sap130(m/m)

[‡] Group B: N 8, Genotype: Pcdha9(m/+) Sap130(m/m)

ABC** vs. WT^{‡‡}

WT

Median

0

0

ABC

Median

1

6

- § Group C: N 7, Genotype: Pcdha9(+/+) Sap130(m/m)
- || Group D: N 4, Genotype: Pcdha9(m/m) Sap130(m/+)
- ¶ Group E: N 0, Genotype: Pcdha9(m/m) Sap130(+/+)
- # Group F: N 27, Genotype: Pcdha9(m/+) or (+/+) Sap130(m/+) or (+/+)
- ** Group ABC: N 39, Genotype: Sap130(m/m), Pcdha9 (*/*)
- †† Group AB: N 32, Genotype: Sap130(m/m), Pcdha9 (m/*)

‡‡ Group WT: N 10

Structure

Hippocampus

Cerebellum

BDS Total

BDS

or